{"DataElement":{"publicId":"3333730","version":"1","preferredName":"Treatment Assignment Treatment Assignment Type","preferredDefinition":"the assignment to a specific treatment._A subdivision of a particular kind of thing for treatment assignment.","longName":"TxAssTp","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2014059","version":"1","preferredName":"Treatment Assignment","preferredDefinition":"the assignment to a specific treatment.","longName":"TX_ASSIGN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176930","version":"1","preferredName":"Treatment","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"Treatment","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7B00-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177638","version":"1","preferredName":"Assignment","preferredDefinition":"Assignment; an undertaking that you have been assigned to do.","longName":"Assignment","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5185-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B31A7164-D7B7-3AD1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for use for AdEERS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3351557","version":"1","preferredName":"Treatment Assignment Type","preferredDefinition":"A subdivision of a particular kind of thing for treatment assignment.","longName":"3351557v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Treatment 2: A,A,A,A","valueDescription":"Treatment 2: A,A,A,A","ValueMeaning":{"publicId":"3412784","version":"1","preferredName":"Treatment 2: A,A,A,A","longName":"3412784","preferredDefinition":"Treatment 2: A,A,A,A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB14476A-3BE5-DFCA-E040-BB89AD4366E1","latestVersionIndicator":"Yes","beginDate":"2012-03-12","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB4FF5FD-786E-C5B5-E040-BB89AD43178F","beginDate":"2012-03-15","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"WONGW","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"Treatment 1: A,B,A,B,A,B","valueDescription":"Treatment 1: A,B,A,B,A,B","ValueMeaning":{"publicId":"3412785","version":"1","preferredName":"Treatment 1: A,B,A,B,A,B","longName":"3412785","preferredDefinition":"Treatment 1: A,B,A,B,A,B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB14476A-3C08-DFCA-E040-BB89AD4366E1","latestVersionIndicator":"Yes","beginDate":"2012-03-12","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB4FF5FD-7882-C5B5-E040-BB89AD43178F","beginDate":"2012-03-15","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"Safety  Arm C:  5.0","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 5.0 mg/kg/day","ValueMeaning":{"publicId":"3350740","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 5.0 mg/kg/day","longName":"3350740","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 5.0 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-7421-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-8286-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Safety  Arm C:  4.25","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 4.25 mg/kg/day","ValueMeaning":{"publicId":"3350741","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 4.25 mg/kg/day","longName":"3350741","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 4.25 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-7444-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-8290-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Safety  Arm C:  4.0","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 4.0 mg/kg/day","ValueMeaning":{"publicId":"3350742","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 4.0 mg/kg/day","longName":"3350742","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 4.0 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-7467-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-829A-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Safety  Arm C:  3.5","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 3.5 mg/kg/day","ValueMeaning":{"publicId":"3350743","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 3.5 mg/kg/day","longName":"3350743","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 3.5 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-748A-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82A4-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Safety  Arm C:  3.0","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 3.0 mg/kg/day","ValueMeaning":{"publicId":"3350744","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 3.0 mg/kg/day","longName":"3350744","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age >/=90 days): 3.0 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-74AD-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82AE-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Safety  Arm C:  2.75","valueDescription":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 2.75 mg/kg/day","ValueMeaning":{"publicId":"3350745","version":"1","preferredName":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 2.75 mg/kg/day","longName":"3350745","preferredDefinition":"Safety Phase - Arm C:  Post Induction Therapy with Lestaurtinib (MLL-R, Age <90 days): 2.75 mg/kg/day","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-74D0-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82B8-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Arm C:  Post Induction","valueDescription":"Arm C:  Post Induction Therapy with Lestaurtinib for MLL-R (IR/HR)","ValueMeaning":{"publicId":"3350746","version":"1","preferredName":"Arm C:  Post Induction Therapy with Lestaurtinib for MLL-R (IR/HR)","longName":"3350746","preferredDefinition":"Arm C:  Post Induction Therapy with Lestaurtinib for MLL-R (IR/HR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-74F3-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82C2-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Arm B:  Post Induction","valueDescription":"Arm B:  Post Induction Therapy without Lestaurtinib for MLL-R (IR/HR)","ValueMeaning":{"publicId":"3350747","version":"1","preferredName":"Arm B:  Post Induction Therapy without Lestaurtinib for MLL-R (IR/HR)","longName":"3350747","preferredDefinition":"Arm B:  Post Induction Therapy without Lestaurtinib for MLL-R (IR/HR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-7516-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82CC-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Arm A:  Post Induction","valueDescription":"Arm A:  Post Induction Therapy for MLL-G (SR","ValueMeaning":{"publicId":"3351558","version":"1","preferredName":"Arm A:  Post Induction Therapy for MLL-G (SR","longName":"3351558","preferredDefinition":"Arm A:  Post Induction Therapy for MLL-G (SR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B658474C-82D6-BD53-E040-BB89AD433481","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82EF-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Induction","valueDescription":"Induction Therapy - Weeks 1 - 5","ValueMeaning":{"publicId":"3350749","version":"1","preferredName":"Induction Therapy - Weeks 1 - 5","longName":"3350749","preferredDefinition":"Induction Therapy - Weeks 1 - 5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B656F415-755C-2E06-E040-BB89AD430E73","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B658474C-82F9-BD53-E040-BB89AD433481","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"ANBL1221 Regimen A","valueDescription":"Regimen A: Irinotecan and Temozolomide and Temsirolimus","ValueMeaning":{"publicId":"3564069","version":"1","preferredName":"Regimen A: Irinotecan and Temozolomide and Temsirolimus","longName":"3564069","preferredDefinition":"ANBL1221 Regimen A: Irinotecan and Temozolomide and Temsirolimus","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CF9003-8F3F-BBBC-E040-BB89AD433BC5","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"WONGW","dateCreated":"2012-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C7CF9003-8F58-BBBC-E040-BB89AD433BC5","beginDate":"2012-08-21","endDate":null,"createdBy":"WONGW","dateCreated":"2012-08-21","modifiedBy":"ONEDATA","dateModified":"2012-08-21","deletedIndicator":"No"},{"value":"Treatment 1  A B A B A B","valueDescription":"Treatment 1: A,B,A,B,A,B","ValueMeaning":{"publicId":"3412785","version":"1","preferredName":"Treatment 1: A,B,A,B,A,B","longName":"3412785","preferredDefinition":"Treatment 1: A,B,A,B,A,B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB14476A-3C08-DFCA-E040-BB89AD4366E1","latestVersionIndicator":"Yes","beginDate":"2012-03-12","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C04017F0-EE81-9A80-E040-BB89AD430E4B","beginDate":"2012-03-15","endDate":null,"createdBy":"WONGW","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"Treatment 2 A A A A","valueDescription":"Treatment 2: A,A,A,A","ValueMeaning":{"publicId":"3412784","version":"1","preferredName":"Treatment 2: A,A,A,A","longName":"3412784","preferredDefinition":"Treatment 2: A,A,A,A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB14476A-3BE5-DFCA-E040-BB89AD4366E1","latestVersionIndicator":"Yes","beginDate":"2012-03-12","endDate":null,"createdBy":"WONGW","dateCreated":"2012-03-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C04017F0-EEC3-9A80-E040-BB89AD430E4B","beginDate":"2012-03-15","endDate":null,"createdBy":"WONGW","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"2838911","version":"1","preferredName":"Not Applicable","longName":"2838911","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A641-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D62D9D6F-71C5-3451-E040-BB89AD434FC4","beginDate":"2013-02-20","endDate":null,"createdBy":"TSANE","dateCreated":"2013-02-20","modifiedBy":"ONEDATA","dateModified":"2013-02-20","deletedIndicator":"No"},{"value":"ASCT1221 Arm B","valueDescription":"Arm B: HCT Conditioning Regimen with Busulfan and Fludarabine","ValueMeaning":{"publicId":"3755999","version":"1","preferredName":"Arm B: HCT Conditioning Regimen with Busulfan and Fludarabine","longName":"3755999","preferredDefinition":"A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.: Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant.: Used to indicate the presence of something or someone.: A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  : A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC4F7EFA-B368-F9B6-E040-BB89AD432191","latestVersionIndicator":"Yes","beginDate":"2013-05-09","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC4F7EFA-B381-F9B6-E040-BB89AD432191","beginDate":"2013-05-09","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-09","modifiedBy":"ONEDATA","dateModified":"2013-05-09","deletedIndicator":"No"},{"value":"ASCT1221 Arm A","valueDescription":"Arm A: HCT Conditioning Regimen with Busulfan and Cyclophosphamide and Melphalan","ValueMeaning":{"publicId":"3755995","version":"1","preferredName":"Arm A: HCT Conditioning Regimen with Busulfan and Cyclophosphamide and Melphalan","longName":"3755995","preferredDefinition":"A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells.: Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant.: Used to indicate the presence of something or someone.: A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC4F6CE0-BCA7-E68A-E040-BB89AD434F62","latestVersionIndicator":"Yes","beginDate":"2013-05-09","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC4F6CE0-BCC0-E68A-E040-BB89AD434F62","beginDate":"2013-05-09","endDate":null,"createdBy":"TSANE","dateCreated":"2013-05-09","modifiedBy":"ONEDATA","dateModified":"2013-05-09","deletedIndicator":"No"},{"value":"Blinded Treatment","valueDescription":"Blinded Treatment","ValueMeaning":{"publicId":"3819309","version":"1","preferredName":"Blinded Treatment","longName":"3819309","preferredDefinition":"Describes an experiment or clinical trial in which patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given.: A type of study protocol designed to evaluate intervention(s) for disease treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded","conceptCode":"C49068","definition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Study","conceptCode":"C49656","definition":"A type of study protocol designed to evaluate intervention(s) for disease treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E236D8CA-8D66-66F4-E040-BB89AD430F12","latestVersionIndicator":"Yes","beginDate":"2013-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2013-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E248E414-301C-6C36-E040-BB89AD433281","beginDate":"2013-07-23","endDate":null,"createdBy":"WONGW","dateCreated":"2013-07-24","modifiedBy":"ONEDATA","dateModified":"2013-07-24","deletedIndicator":"No"},{"value":"ACNS1221 Treatment","valueDescription":"Induction Chemotherapy (3 cycles) followed by Continuation Therapy (2 cycles)","ValueMeaning":{"publicId":"3918264","version":"1","preferredName":"Induction Chemotherapy (3 cycles) followed by Continuation Therapy (2 cycles)","longName":"3918264","preferredDefinition":"Induction Chemotherapy (3 cycles) followed by Continuation Therapy (2 cycles)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8668018-BBE0-D2E1-E040-BB89AD43200C","latestVersionIndicator":"Yes","beginDate":"2013-10-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-10-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E86AFB46-A565-D372-E040-BB89AD4310B0","beginDate":"2013-10-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-10-10","modifiedBy":"ONEDATA","dateModified":"2013-10-10","deletedIndicator":"No"},{"value":"ANHL12P1 Arm CZ","valueDescription":"Chemotherapy And Crizotinib","ValueMeaning":{"publicId":"3891261","version":"1","preferredName":"Chemotherapy And Crizotinib","longName":"3891261","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E60D14E2-807C-56E4-E040-BB89AD430F6D","latestVersionIndicator":"Yes","beginDate":"2013-09-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E69A93D1-E37A-3E55-E040-BB89AD435B2F","beginDate":"2013-09-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-17","modifiedBy":"ONEDATA","dateModified":"2013-09-17","deletedIndicator":"No"},{"value":"ANHL12P1 Arm BV","valueDescription":"Chemotherapy And Brentuximab Vedotin","ValueMeaning":{"publicId":"3891262","version":"1","preferredName":"Chemotherapy And Brentuximab Vedotin","longName":"3891262","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E60D14E2-80A3-56E4-E040-BB89AD430F6D","latestVersionIndicator":"Yes","beginDate":"2013-09-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E69A93D1-E364-3E55-E040-BB89AD435B2F","beginDate":"2013-09-10","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-17","modifiedBy":"ONEDATA","dateModified":"2013-09-17","deletedIndicator":"No"},{"value":"Control Cleansing","valueDescription":"Control Cleansing","ValueMeaning":{"publicId":"3895586","version":"1","preferredName":"Control Cleansing","longName":"3895586","preferredDefinition":"Control Cleansing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E634EB31-C8D1-1880-E040-BB89AD43666F","latestVersionIndicator":"Yes","beginDate":"2013-09-12","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E634EB31-C8EA-1880-E040-BB89AD43666F","beginDate":"2013-09-12","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-12","modifiedBy":"ONEDATA","dateModified":"2013-09-12","deletedIndicator":"No"},{"value":"CHG Cleansing","valueDescription":"CHG Cleansing","ValueMeaning":{"publicId":"3895587","version":"1","preferredName":"CHG Cleansing","longName":"3895587","preferredDefinition":"CHG Cleansing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E634EB31-C8F4-1880-E040-BB89AD43666F","latestVersionIndicator":"Yes","beginDate":"2013-09-12","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E634EB31-C90D-1880-E040-BB89AD43666F","beginDate":"2013-09-12","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-12","modifiedBy":"ONEDATA","dateModified":"2013-09-12","deletedIndicator":"No"},{"value":"ADVL1321 Treatment","valueDescription":"Imetelstat 285 mg/m2/IV over 2 hours on Days 1 and 8 every 21 days, repeatable up to 35 cycles","ValueMeaning":{"publicId":"3982413","version":"1","preferredName":"Imetelstat 285 mg/m2/IV over 2 hours on Days 1 and 8 every 21 days, repeatable up to 35 cycles","longName":"3982413","preferredDefinition":"Imetelstat 285 mg/m2/IV over 2 hours on Days 1 and 8 every 21 days, repeatable up to 35 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED1DC90C-C2CD-0A82-E040-BB89AD43087F","latestVersionIndicator":"Yes","beginDate":"2013-12-09","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED1DC90C-C2E6-0A82-E040-BB89AD43087F","beginDate":"2013-12-09","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-09","modifiedBy":"ONEDATA","dateModified":"2013-12-09","deletedIndicator":"No"},{"value":"ARET12P1 Treatment","valueDescription":"Intra-arterial Chemotherapy","ValueMeaning":{"publicId":"4119752","version":"1","preferredName":"Intra-arterial Chemotherapy","longName":"4119752","preferredDefinition":"Within an artery (blood vessel that carries blood from the heart to tissues and organs in the body).: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intra-arterial","conceptCode":"C94248","definition":"Within an artery (blood vessel that carries blood from the heart to tissues and organs in the body).","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F11EB45A-B7DC-486F-E040-BB89AD436DF8","latestVersionIndicator":"Yes","beginDate":"2014-01-29","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F11EB45A-B7F5-486F-E040-BB89AD436DF8","beginDate":"2014-01-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-01-29","modifiedBy":"ONEDATA","dateModified":"2014-01-29","deletedIndicator":"No"},{"value":"ARST1321 Regimen A","valueDescription":"Regimen A: Chemoradiation plus pazopanib","ValueMeaning":{"publicId":"4231087","version":"1","preferredName":"Regimen A: Chemoradiation plus pazopanib","longName":"4231087","preferredDefinition":"Regimen A: Chemoradiation plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-5734-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4D287E2-574D-4F14-E040-BB89AD43579C","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"ONEDATA","dateModified":"2014-03-17","deletedIndicator":"No"},{"value":"ARST1321 Regimen B","valueDescription":"Regimen B: Chemoradiation alone","ValueMeaning":{"publicId":"4231088","version":"1","preferredName":"Regimen B: Chemoradiation alone","longName":"4231088","preferredDefinition":"Regimen B: Chemoradiation alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-5757-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4D287E2-5770-4F14-E040-BB89AD43579C","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"ONEDATA","dateModified":"2014-03-17","deletedIndicator":"No"},{"value":"ARST1321 Regimen C","valueDescription":"Regimen C: Radiation therapy plus pazopanib","ValueMeaning":{"publicId":"4231089","version":"1","preferredName":"Regimen C: Radiation therapy plus pazopanib","longName":"4231089","preferredDefinition":"Regimen C: Radiation therapy plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-577A-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4D287E2-5793-4F14-E040-BB89AD43579C","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"ONEDATA","dateModified":"2014-03-17","deletedIndicator":"No"},{"value":"ARST1321 Regimen D","valueDescription":"Regimen D: Radiation therapy alone","ValueMeaning":{"publicId":"4231090","version":"1","preferredName":"Regimen D: Radiation therapy alone","longName":"4231090","preferredDefinition":"Regimen D: Radiation therapy alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-579D-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4D287E2-57B6-4F14-E040-BB89AD43579C","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"ONEDATA","dateModified":"2014-03-17","deletedIndicator":"No"},{"value":"AOST1322 Treatment","valueDescription":"Eribulin","ValueMeaning":{"publicId":"4311896","version":"1","preferredName":"Eribulin","longName":"4311896","preferredDefinition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eribulin","conceptCode":"C96748","definition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96171AF-8CBE-CD50-E040-BB89AD436A46","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F979B481-05D3-E8AC-E040-BB89AD431FBF","beginDate":"2014-05-09","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-15","modifiedBy":"ONEDATA","dateModified":"2014-05-15","deletedIndicator":"No"},{"value":"First-Line Chemotherapy","valueDescription":"First-Line Chemotherapy","ValueMeaning":{"publicId":"4358771","version":"1","preferredName":"First-Line Chemotherapy","longName":"4358771","preferredDefinition":"First-Line Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC0C635D-9201-81B6-E040-BB89AD43280E","latestVersionIndicator":"Yes","beginDate":"2014-06-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC0C635D-921A-81B6-E040-BB89AD43280E","beginDate":"2014-06-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-17","modifiedBy":"ONEDATA","dateModified":"2014-06-17","deletedIndicator":"No"},{"value":"Observation","valueDescription":"Observation","ValueMeaning":{"publicId":"2576712","version":"1","preferredName":"Observation","longName":"2576712","preferredDefinition":"Observation; watching something and taking note of what happens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Observation","conceptCode":"C25598","definition":"Watching something and taking note of what happens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-27","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-10-27","modifiedBy":"ONEDATA","dateModified":"2005-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC0C635D-9224-81B6-E040-BB89AD43280E","beginDate":"2014-06-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-06-17","modifiedBy":"ONEDATA","dateModified":"2014-06-17","deletedIndicator":"No"},{"value":"AEWS1221 Regimen B","valueDescription":"Regimen B: VDC/IE and ganitumab","ValueMeaning":{"publicId":"4204356","version":"1","preferredName":"Regimen B: VDC/IE and ganitumab","longName":"4204356","preferredDefinition":"AEWS1221 Regimen B: VinCRIStine Doxorubicin Cyclophosphamide/Ifosfamide Etoposide and ganitumab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F40B9346-BCB0-E958-E040-BB89AD4348B8","latestVersionIndicator":"Yes","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40B9346-BCC9-E958-E040-BB89AD4348B8","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"ONEDATA","dateModified":"2014-03-07","deletedIndicator":"No"},{"value":"AEWS1221 Regimen A","valueDescription":"Regimen A: VDC/IE","ValueMeaning":{"publicId":"4204357","version":"1","preferredName":"Regimen A: VDC/IE","longName":"4204357","preferredDefinition":"AEWS1221 Regimen A: VinCRIStine Doxorubicin Cyclophosphamide/Ifosfamide Etoposide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F40B9346-BCD3-E958-E040-BB89AD4348B8","latestVersionIndicator":"Yes","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40B9346-BCEC-E958-E040-BB89AD4348B8","beginDate":"2014-03-07","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-07","modifiedBy":"ONEDATA","dateModified":"2014-03-07","deletedIndicator":"No"},{"value":"ANBL1221 Regimen B (UTC)","valueDescription":"Regimen B (UTC): Irinotecan and Temozolomide and ch14.18 (17.5 mg/m2) with GM-CSF","ValueMeaning":{"publicId":"4356965","version":"1","preferredName":"Regimen B (UTC): Irinotecan and Temozolomide and ch14.18 (17.5 mg/m2) with GM-CSF","longName":"4356965","preferredDefinition":"ANBL1221 Regimen B (UTC): Irinotecan and Temozolomide and ch14.18 (17.5 mg/m2) with GM-CSF","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB96850C-15BC-4EE5-E040-BB89AD430F07","latestVersionIndicator":"Yes","beginDate":"2014-06-11","endDate":null,"createdBy":"WONGW","dateCreated":"2014-06-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB96850C-15D5-4EE5-E040-BB89AD430F07","beginDate":"2014-06-11","endDate":null,"createdBy":"WONGW","dateCreated":"2014-06-11","modifiedBy":"ONEDATA","dateModified":"2014-06-11","deletedIndicator":"No"},{"value":"ANBL1221 Regimen B","valueDescription":"Regimen B: Irinotecan and Temozolomide and ch14.18 with GM-CSF","ValueMeaning":{"publicId":"3564070","version":"1","preferredName":"Regimen B: Irinotecan and Temozolomide and ch14.18 with GM-CSF","longName":"3564070","preferredDefinition":"ANBL1221 Regimen B: Irinotecan and Temozolomide and ch14.18 with GM-CSF","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CF9003-8F62-BBBC-E040-BB89AD433BC5","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"WONGW","dateCreated":"2012-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB96850C-15E9-4EE5-E040-BB89AD430F07","beginDate":"2012-08-21","endDate":null,"createdBy":"WONGW","dateCreated":"2014-06-11","modifiedBy":"ONEDATA","dateModified":"2014-06-11","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 0 RT","valueDescription":"Dose-Finding Dose Level 0 RT: Radiation therapy plus pazopanib","ValueMeaning":{"publicId":"4231082","version":"1","preferredName":"Dose-Finding Dose Level 0 RT: Radiation therapy plus pazopanib","longName":"4231082","preferredDefinition":"Dose-Finding Dose Level 0 RT: Radiation therapy plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-5685-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5A58-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 0 CR","valueDescription":"Dose-Finding Dose Level 0 CR: Chemoradiation plus pazopanib","ValueMeaning":{"publicId":"4231081","version":"1","preferredName":"Dose-Finding Dose Level 0 CR: Chemoradiation plus pazopanib","longName":"4231081","preferredDefinition":"Dose-Finding Dose Level 0 CR: Chemoradiation plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-5662-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5A44-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 1 CR","valueDescription":"Dose-Finding Dose Level 1 CR: Chemoradiation plus pazopanib","ValueMeaning":{"publicId":"4231083","version":"1","preferredName":"Dose-Finding Dose Level 1 CR: Chemoradiation plus pazopanib","longName":"4231083","preferredDefinition":"Dose-Finding Dose Level 1 CR: Chemoradiation plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-56A8-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5A6C-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 1 RT","valueDescription":"Dose-Finding Dose Level 1 RT: Radiation therapy plus pazopanib","ValueMeaning":{"publicId":"4231084","version":"1","preferredName":"Dose-Finding Dose Level 1 RT: Radiation therapy plus pazopanib","longName":"4231084","preferredDefinition":"Dose-Finding Dose Level 1 RT: Radiation therapy plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-56CB-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5A80-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 2 CR","valueDescription":"Dose-Finding Dose Level 2 CR: Chemoradiation plus pazopanib","ValueMeaning":{"publicId":"4231085","version":"1","preferredName":"Dose-Finding Dose Level 2 CR: Chemoradiation plus pazopanib","longName":"4231085","preferredDefinition":"Dose-Finding Dose Level 2 CR: Chemoradiation plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-56EE-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5A94-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ARST1321 Dose Level 2 RT","valueDescription":"Dose-Finding Dose Level 2 RT: Radiation therapy plus pazopanib","ValueMeaning":{"publicId":"4231086","version":"1","preferredName":"Dose-Finding Dose Level 2 RT: Radiation therapy plus pazopanib","longName":"4231086","preferredDefinition":"Dose-Finding Dose Level 2 RT: Radiation therapy plus pazopanib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D287E2-5711-4F14-E040-BB89AD43579C","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B07554-5AA8-0635-E040-BB89AD436D02","beginDate":"2014-03-17","endDate":null,"createdBy":"TSANE","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"AALL1231 Arm B","valueDescription":"Arm B: Treatment WITH Bortezomib","ValueMeaning":{"publicId":"4397691","version":"1","preferredName":"Arm B: Treatment WITH Bortezomib","longName":"4397691","preferredDefinition":"AALL1231 Arm B: Treatment WITH Bortezomib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FECF4695-FCB5-CD6E-E040-BB89AD43670A","latestVersionIndicator":"Yes","beginDate":"2014-07-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FECF4695-FCCE-CD6E-E040-BB89AD43670A","beginDate":"2014-07-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-22","modifiedBy":"ONEDATA","dateModified":"2014-07-22","deletedIndicator":"No"},{"value":"AALL1231 Arm A","valueDescription":"Arm A: Treatment WITHOUT Bortezomib","ValueMeaning":{"publicId":"4397692","version":"1","preferredName":"Arm A: Treatment WITHOUT Bortezomib","longName":"4397692","preferredDefinition":"AALL1231 Arm A: Treatment WITHOUT Bortezomib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FECF4695-FCD8-CD6E-E040-BB89AD43670A","latestVersionIndicator":"Yes","beginDate":"2014-07-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FECF4695-FCF1-CD6E-E040-BB89AD43670A","beginDate":"2014-07-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-22","modifiedBy":"ONEDATA","dateModified":"2014-07-22","deletedIndicator":"No"},{"value":"Observation/Chemotherapy","valueDescription":"Observation/Chemotherapy","ValueMeaning":{"publicId":"4386591","version":"1","preferredName":"Observation/Chemotherapy","longName":"4386591","preferredDefinition":"Observation/Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE6C653B-2759-F06C-E040-BB89AD434F63","latestVersionIndicator":"Yes","beginDate":"2014-07-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE6C653B-2772-F06C-E040-BB89AD434F63","beginDate":"2014-07-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-07-17","modifiedBy":"ONEDATA","dateModified":"2014-07-17","deletedIndicator":"No"},{"value":"Block 1","valueDescription":"Block 1","ValueMeaning":{"publicId":"4488109","version":"1","preferredName":"Block 1","longName":"4488109","preferredDefinition":"Block 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"037141AD-BD02-95DE-E050-BB89AD430B40","latestVersionIndicator":"Yes","beginDate":"2014-09-19","endDate":null,"createdBy":"WONGW","dateCreated":"2014-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04D91583-CCE3-CE64-E050-BB89AD43335F","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"ONEDATA","dateModified":"2014-10-07","deletedIndicator":"No"},{"value":"AHOD1331 ABVE-PC","valueDescription":"ABVE-PC","ValueMeaning":{"publicId":"4642800","version":"1","preferredName":"ABVE-PC","longName":"4642800","preferredDefinition":"AHOD1331 Treatment 10: ABVE-PC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A9B7E16-CCBF-A62F-E050-BB89AD430BB8","latestVersionIndicator":"Yes","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E61A7A1-8F4B-DF3D-E050-BB89AD43606A","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-02-05","modifiedBy":"ONEDATA","dateModified":"2015-02-05","deletedIndicator":"No"},{"value":"AHOD1331 Bv-AVEPC","valueDescription":"Bv-AVEPC","ValueMeaning":{"publicId":"4642799","version":"1","preferredName":"Bv-AVEPC","longName":"4642799","preferredDefinition":"AHOD1331 Treatment 20: Bv-AVEPC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A9B7E16-CC9C-A62F-E050-BB89AD430BB8","latestVersionIndicator":"Yes","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E61A7A1-8F62-DF3D-E050-BB89AD43606A","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-02-05","modifiedBy":"ONEDATA","dateModified":"2015-02-05","deletedIndicator":"No"},{"value":"AALL1331 Salvage Therapy","valueDescription":"Salvage Therapy (Blinatumomab-S)","ValueMeaning":{"publicId":"4633571","version":"1","preferredName":"Salvage Therapy (Blinatumomab-S)","longName":"4633571","preferredDefinition":"Salvage Therapy (Blinatumomab-S)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A44E1CD-92E0-6BD9-E050-BB89AD432C7A","latestVersionIndicator":"Yes","beginDate":"2014-12-15","endDate":null,"createdBy":"WONGW","dateCreated":"2014-12-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A479374-FF2E-10BA-E050-BB89AD436A1F","beginDate":"2014-12-15","endDate":null,"createdBy":"WONGW","dateCreated":"2014-12-15","modifiedBy":"ONEDATA","dateModified":"2014-12-15","deletedIndicator":"No"},{"value":"AALL1331 Arm B","valueDescription":"Arm B","ValueMeaning":{"publicId":"2571807","version":"1","preferredName":"Arm B","longName":"2571807","preferredDefinition":"Treatment Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E58C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"CAMPBELB","dateModified":"2004-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0697775B-6BDC-F5BF-E050-BB89AD434D45","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"AALL1331 Arm A","valueDescription":"Arm A","ValueMeaning":{"publicId":"2571806","version":"1","preferredName":"Arm A","longName":"2571806","preferredDefinition":"Treatment Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E58B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-08","modifiedBy":"CAMPBELB","dateModified":"2004-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0697775B-6BF0-F5BF-E050-BB89AD434D45","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"AALL1331 Arm C","valueDescription":"Arm C","ValueMeaning":{"publicId":"4566611","version":"1","preferredName":"Arm C","longName":"4566611","preferredDefinition":"Treatment Arm C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0697D215-C860-8D17-E050-BB89AD434DD7","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0697D215-C878-8D17-E050-BB89AD434DD7","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"AALL1331 Arm D","valueDescription":"Arm D","ValueMeaning":{"publicId":"4566612","version":"1","preferredName":"Arm D","longName":"4566612","preferredDefinition":"Treatment Arm D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0697D215-C883-8D17-E050-BB89AD434DD7","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0697D215-C89B-8D17-E050-BB89AD434DD7","beginDate":"2014-10-29","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"AHOD1331 Treatment 20","valueDescription":"Bv-AVEPC","ValueMeaning":{"publicId":"4642799","version":"1","preferredName":"Bv-AVEPC","longName":"4642799","preferredDefinition":"AHOD1331 Treatment 20: Bv-AVEPC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A9B7E16-CC9C-A62F-E050-BB89AD430BB8","latestVersionIndicator":"Yes","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A9B7E16-CCB5-A62F-E050-BB89AD430BB8","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"CORRALC","dateModified":"2015-02-05","deletedIndicator":"No"},{"value":"AHOD1331 Treatment 10","valueDescription":"ABVE-PC","ValueMeaning":{"publicId":"4642800","version":"1","preferredName":"ABVE-PC","longName":"4642800","preferredDefinition":"AHOD1331 Treatment 10: ABVE-PC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A9B7E16-CCBF-A62F-E050-BB89AD430BB8","latestVersionIndicator":"Yes","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A9B7E16-CCD8-A62F-E050-BB89AD430BB8","beginDate":"2014-12-19","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-19","modifiedBy":"CORRALC","dateModified":"2015-02-05","deletedIndicator":"No"},{"value":"ADVL1522 Dose Level -1","valueDescription":"ADVL1522 Dose Level -1: IMGN901 90 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","ValueMeaning":{"publicId":"4843814","version":"1","preferredName":"ADVL1522 Dose Level -1: IMGN901 90 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","longName":"4843814","preferredDefinition":"ADVL1522 Dose Level -1: IMGN901 90 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"177C85A0-173D-19F5-E050-BB89AD433AB0","latestVersionIndicator":"Yes","beginDate":"2015-06-01","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"177C85A0-1756-19F5-E050-BB89AD433AB0","beginDate":"2015-06-01","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-01","modifiedBy":"ONEDATA","dateModified":"2015-06-01","deletedIndicator":"No"},{"value":"ADVL1522 Dose Level 1","valueDescription":"ADVL1522 Dose Level 1: IMGN901 110 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","ValueMeaning":{"publicId":"4843815","version":"1","preferredName":"ADVL1522 Dose Level 1: IMGN901 110 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","longName":"4843815","preferredDefinition":"ADVL1522 Dose Level 1: IMGN901 110 mg/m2/IV over 1-1.5 hours on Days 1 and 8 every 21 days, repeatable up to 17 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"177C85A0-1760-19F5-E050-BB89AD433AB0","latestVersionIndicator":"Yes","beginDate":"2015-06-01","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"177C85A0-1779-19F5-E050-BB89AD433AB0","beginDate":"2015-06-01","endDate":null,"createdBy":"CORRALC","dateCreated":"2015-06-01","modifiedBy":"ONEDATA","dateModified":"2015-06-01","deletedIndicator":"No"},{"value":"AOST1321 Treatment","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"17913482-229E-4840-E050-BB89AD435769","beginDate":"2015-06-02","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-02","modifiedBy":"ONEDATA","dateModified":"2015-06-02","deletedIndicator":"No"},{"value":"Standard Risk Therapy","valueDescription":"Standard Risk Therapy","ValueMeaning":{"publicId":"4718305","version":"1","preferredName":"Standard Risk Therapy","longName":"4718305","preferredDefinition":"Standard Risk Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EFBF462-7161-C765-E050-BB89AD435E2D","latestVersionIndicator":"Yes","beginDate":"2015-02-13","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EFBF462-717A-C765-E050-BB89AD435E2D","beginDate":"2015-02-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-13","modifiedBy":"ONEDATA","dateModified":"2015-02-13","deletedIndicator":"No"},{"value":"High Risk Therapy","valueDescription":"High Risk Therapy","ValueMeaning":{"publicId":"4718306","version":"1","preferredName":"High Risk Therapy","longName":"4718306","preferredDefinition":"High Risk Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EFBF462-7184-C765-E050-BB89AD435E2D","latestVersionIndicator":"Yes","beginDate":"2015-02-13","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EFBF462-719D-C765-E050-BB89AD435E2D","beginDate":"2015-02-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-02-13","modifiedBy":"ONEDATA","dateModified":"2015-02-13","deletedIndicator":"No"},{"value":"Induction I","valueDescription":"Induction I","ValueMeaning":{"publicId":"4839598","version":"1","preferredName":"Induction I","longName":"4839598","preferredDefinition":"Induction I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17163B1B-8DE8-BE38-E050-BB89AD43266A","latestVersionIndicator":"Yes","beginDate":"2015-05-27","endDate":null,"createdBy":"LEEW","dateCreated":"2015-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E78B0A-9558-A24B-E050-BB89AD43665D","beginDate":"2015-05-27","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-02","modifiedBy":"ONEDATA","dateModified":"2015-07-02","deletedIndicator":"No"},{"value":"AAML1531 Arm B","valueDescription":"Arm B: High Risk (MRD > 0.05%)","ValueMeaning":{"publicId":"4890591","version":"1","preferredName":"Arm B: High Risk (MRD > 0.05%)","longName":"4890591","preferredDefinition":"AAML1531 Arm B: High Risk (MRD > 0.05%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E739FA-2AB4-04D7-E050-BB89AD436C67","latestVersionIndicator":"Yes","beginDate":"2015-07-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E739FA-2ACD-04D7-E050-BB89AD436C67","beginDate":"2015-06-05","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-02","modifiedBy":"ONEDATA","dateModified":"2015-07-02","deletedIndicator":"No"},{"value":"AAML1531 Arm A","valueDescription":"Arm A: Standard Risk (MRD <0.05%)","ValueMeaning":{"publicId":"4890592","version":"1","preferredName":"Arm A: Standard Risk (MRD <0.05%)","longName":"4890592","preferredDefinition":"AAML1531 Arm A: Standard Risk (MRD <0.05%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E739FA-2AD7-04D7-E050-BB89AD436C67","latestVersionIndicator":"Yes","beginDate":"2015-07-02","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E739FA-2AF0-04D7-E050-BB89AD436C67","beginDate":"2015-06-05","endDate":null,"createdBy":"WONGW","dateCreated":"2015-07-02","modifiedBy":"ONEDATA","dateModified":"2015-07-02","deletedIndicator":"No"},{"value":"AOST1521 Treatment","valueDescription":"CDX-011 at 1.9 mg/kg intravenously over 90 minutes every 21 days","ValueMeaning":{"publicId":"5073083","version":"1","preferredName":"CDX-011 at 1.9 mg/kg intravenously over 90 minutes every 21 days","longName":"5073083","preferredDefinition":"CDX-011 at 1.9 mg/kg intravenously over 90 minutes every 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2616CDC6-EA9C-A9BA-E050-BB89AD437381","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2616CDC6-EAB5-A9BA-E050-BB89AD437381","beginDate":"2015-12-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"AOST1421 Treatment","valueDescription":"Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"3597790","version":"1","preferredName":"Monoclonal Antibody Ch14.18","longName":"3597790","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E763-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1EF3F633-FDA1-4366-E050-BB89AD43305F","beginDate":"2015-09-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-09-04","modifiedBy":"ONEDATA","dateModified":"2015-09-04","deletedIndicator":"No"},{"value":"AAML1421 Treatment Dose Level 0","valueDescription":"Dose Level 0: 100 Units/m2/dose","ValueMeaning":{"publicId":"5115269","version":"1","preferredName":"Dose Level 0: 100 Units/m2/dose","longName":"5115269","preferredDefinition":"AAML1421 Treatment Dose Level 0: 100 Units/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A6B3C47-F331-6495-E050-BB89AD436F6E","latestVersionIndicator":"Yes","beginDate":"2016-01-28","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2A6B3C47-F34A-6495-E050-BB89AD436F6E","beginDate":"2015-11-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"MIRANDAA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"AAML1421 Treatment Dose Level 1","valueDescription":"Dose Level 1: 135 Units/m2/dose","ValueMeaning":{"publicId":"5115270","version":"1","preferredName":"Dose Level 1: 135 Units/m2/dose","longName":"5115270","preferredDefinition":"AAML1421 Treatment Dose Level 1: 135 Units/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A6B3C47-F357-6495-E050-BB89AD436F6E","latestVersionIndicator":"Yes","beginDate":"2016-01-28","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2A6B3C47-F47A-6495-E050-BB89AD436F6E","beginDate":"2015-11-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"MIRANDAA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"AAML1421 Dose Level 1","valueDescription":"Dose Level 1: 135 Units/m2/dose","ValueMeaning":{"publicId":"5115270","version":"1","preferredName":"Dose Level 1: 135 Units/m2/dose","longName":"5115270","preferredDefinition":"AAML1421 Treatment Dose Level 1: 135 Units/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A6B3C47-F357-6495-E050-BB89AD436F6E","latestVersionIndicator":"Yes","beginDate":"2016-01-28","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2ACD3D09-971C-A21F-E050-BB89AD435E77","beginDate":"2015-11-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-02-02","modifiedBy":"ONEDATA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"AAML1421 Dose Level 0","valueDescription":"Dose Level 0: 100 Units/m2/dose","ValueMeaning":{"publicId":"5115269","version":"1","preferredName":"Dose Level 0: 100 Units/m2/dose","longName":"5115269","preferredDefinition":"AAML1421 Treatment Dose Level 0: 100 Units/m2/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A6B3C47-F331-6495-E050-BB89AD436F6E","latestVersionIndicator":"Yes","beginDate":"2016-01-28","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2ACD3D09-9705-A21F-E050-BB89AD435E77","beginDate":"2015-11-09","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-02-02","modifiedBy":"ONEDATA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"RT then Maintenance Chemo","valueDescription":"Radiation Therapy followed by Maintenance Chemotherapy (7 cycles)","ValueMeaning":{"publicId":"5242076","version":"1","preferredName":"Radiation Therapy followed by Maintenance Chemotherapy (7 cycles)","longName":"5242076","preferredDefinition":"Radiation Therapy followed by Maintenance Chemotherapy (7 cycles)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31E17E92-76FB-2840-E050-BB89AD432A6A","latestVersionIndicator":"Yes","beginDate":"2016-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"353E7136-282C-4378-E050-BB89AD432D5C","beginDate":"2016-06-14","endDate":null,"createdBy":"PWEST","dateCreated":"2016-06-14","modifiedBy":"ONEDATA","dateModified":"2016-06-14","deletedIndicator":"No"},{"value":"ARST1431 Regimen C","valueDescription":"Regimen C:  VAC/VA Only","ValueMeaning":{"publicId":"5159818","version":"1","preferredName":"Regimen C:  VAC/VA Only","longName":"5159818","preferredDefinition":"ARST1431 Regimen C:  VAC/VA Only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DD43-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DD5C-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ARST1431 Regimen B","valueDescription":"Regimen B:  VAC/VI + TORI","ValueMeaning":{"publicId":"5159819","version":"1","preferredName":"Regimen B:  VAC/VI + TORI","longName":"5159819","preferredDefinition":"ARST1431 Regimen B:  VAC/VI + TORI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DD66-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DD7F-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ARST1431 Regimen A","valueDescription":"Regimen A:  VAC/VI Only","ValueMeaning":{"publicId":"5159820","version":"1","preferredName":"Regimen A:  VAC/VI Only","longName":"5159820","preferredDefinition":"ARST1431 Regimen A:  VAC/VI Only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DD89-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DDA2-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ARST1431 Feasibility -1","valueDescription":"Feasibility phase:  VAC/VI + TORI (dose level -1)","ValueMeaning":{"publicId":"5159821","version":"1","preferredName":"Feasibility phase:  VAC/VI + TORI (dose level -1)","longName":"5159821","preferredDefinition":"ARST1431 Feasibility phase:  VAC/VI + TORI (dose level -1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DDAC-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DDC5-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ARST1431 Feasibility 0","valueDescription":"Feasibility phase:  VAC/VI + TORI (dose level 0)","ValueMeaning":{"publicId":"5159822","version":"1","preferredName":"Feasibility phase:  VAC/VI + TORI (dose level 0)","longName":"5159822","preferredDefinition":"ARST1431 Feasibility phase:  VAC/VI + TORI (dose level 0)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DDCF-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DDE8-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ARST1431 Feasibility 1","valueDescription":"Feasibility phase:  VAC/VI + TORI (dose level 1)","ValueMeaning":{"publicId":"5159823","version":"1","preferredName":"Feasibility phase:  VAC/VI + TORI (dose level 1)","longName":"5159823","preferredDefinition":"ARST1431 Feasibility phase:  VAC/VI + TORI (dose level 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E2E198F-DDF2-EAD9-E050-BB89AD435A74","latestVersionIndicator":"Yes","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E2E198F-DE0B-EAD9-E050-BB89AD435A74","beginDate":"2016-03-16","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-16","modifiedBy":"ONEDATA","dateModified":"2016-03-16","deletedIndicator":"No"},{"value":"ANHL1522 Treatment 30","valueDescription":"Course LMP-TC1","ValueMeaning":{"publicId":"5509683","version":"1","preferredName":"Course LMP-TC1","longName":"5509683","preferredDefinition":"ANHL1522 Treatment 30: Course LMP-TC1 2 x 10^7 cells/m2/dose IV over 1-2 minutes on Days 0, 7 last 6 weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EAE2E1D-5A64-46E6-E053-F662850AB56D","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EAE2E1D-5A7D-46E6-E053-F662850AB56D","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"ANHL1522 Treatment 20","valueDescription":"Course RTX2","ValueMeaning":{"publicId":"5509684","version":"1","preferredName":"Course RTX2","longName":"5509684","preferredDefinition":"ANHL1522 Treatment 20: Course RTX2 375 mg/m2/dose IV Infusion on Days 1, 8, 15 last 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EAE2E1D-5A87-46E6-E053-F662850AB56D","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EAE2E1D-5AA0-46E6-E053-F662850AB56D","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"ANHL1522 Treatment 10","valueDescription":"Course RTX1","ValueMeaning":{"publicId":"5509685","version":"1","preferredName":"Course RTX1","longName":"5509685","preferredDefinition":"ANHL1522 Treatment 10: Course RTX1 375 mg/m2/dose IV Infusion on Days 1, 8, 15 last 21 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EAE2E1D-5AAA-46E6-E053-F662850AB56D","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3EAE2E1D-5AC3-46E6-E053-F662850AB56D","beginDate":"2016-10-12","endDate":null,"createdBy":"WONGW","dateCreated":"2016-10-12","modifiedBy":"ONEDATA","dateModified":"2016-10-12","deletedIndicator":"No"},{"value":"XL184 (40mg/m2/day)","valueDescription":"XL184 (40mg/m2/day)","ValueMeaning":{"publicId":"5554862","version":"1","preferredName":"XL184 (40mg/m2/day)","longName":"5554862","preferredDefinition":"XL184 (40mg/m2/day)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FF34D5E-6C59-2460-E053-F662850AC4CC","latestVersionIndicator":"Yes","beginDate":"2016-10-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FF34D5E-6C72-2460-E053-F662850AC4CC","beginDate":"2016-10-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-28","modifiedBy":"ONEDATA","dateModified":"2016-10-28","deletedIndicator":"No"},{"value":"Dose Level 0: 1.8 mg/kg/dose","valueDescription":"Dose Level 0: 1.8 mg/kg/dose","ValueMeaning":{"publicId":"5557749","version":"1","preferredName":"Dose Level 0: 1.8 mg/kg/dose","longName":"5557749","preferredDefinition":"Dose Level 0: 1.8 mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"402E8EB9-209D-03B1-E053-F662850A3421","latestVersionIndicator":"Yes","beginDate":"2016-10-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"402E8EB9-20B6-03B1-E053-F662850A3421","beginDate":"2016-10-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-31","modifiedBy":"ONEDATA","dateModified":"2016-10-31","deletedIndicator":"No"},{"value":"Dose Level 1: 2.5 mg/kg/dose","valueDescription":"Dose Level 1: 2.5 mg/kg/dose","ValueMeaning":{"publicId":"5557750","version":"1","preferredName":"Dose Level 1: 2.5 mg/kg/dose","longName":"5557750","preferredDefinition":"Dose Level 1: 2.5 mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"402E8EB9-20C0-03B1-E053-F662850A3421","latestVersionIndicator":"Yes","beginDate":"2016-10-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"402E8EB9-20D9-03B1-E053-F662850A3421","beginDate":"2016-10-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-31","modifiedBy":"ONEDATA","dateModified":"2016-10-31","deletedIndicator":"No"},{"value":"InO + IT Chemotherapy","valueDescription":"Inotuzumab Ozogamicin (InO) + IT Chemotherapy","ValueMeaning":{"publicId":"5577145","version":"1","preferredName":"Inotuzumab Ozogamicin (InO) + IT Chemotherapy","longName":"5577145","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415C998E-DB2C-1F72-E053-F662850A6021","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41810A8A-FCF3-62D7-E053-F662850A2405","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"ALTE1631 Arm B","valueDescription":"Activity monitor plus Limited Access to a Reward-Based Website","ValueMeaning":{"publicId":"5677320","version":"1","preferredName":"Activity monitor plus Limited Access to a Reward-Based Website","longName":"5677320","preferredDefinition":"ALTE1631 Arm B: Activity monitor plus Limited Access to a Reward-Based Website","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"493ACC13-73FF-51EF-E053-F662850A66D2","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"493ACC13-7418-51EF-E053-F662850A66D2","beginDate":"2017-02-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-23","modifiedBy":"ONEDATA","dateModified":"2017-02-23","deletedIndicator":"No"},{"value":"ALTE1631 Arm A","valueDescription":"Activity monitor plus Full Access to an Interactive Reward-Based Website","ValueMeaning":{"publicId":"5677321","version":"1","preferredName":"Activity monitor plus Full Access to an Interactive Reward-Based Website","longName":"5677321","preferredDefinition":"ALTE1631 Arm A: Activity monitor plus Full Access to an Interactive Reward-Based Website","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"493ACC13-7422-51EF-E053-F662850A66D2","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"493ACC13-743B-51EF-E053-F662850A66D2","beginDate":"2017-02-23","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-23","modifiedBy":"ONEDATA","dateModified":"2017-02-23","deletedIndicator":"No"},{"value":"Induction Cycle 1 with Topotecan + Cyclophosphamide","valueDescription":"Induction Cycle 1 with Topotecan + Cyclophosphamide","ValueMeaning":{"publicId":"5678514","version":"1","preferredName":"Induction Cycle 1 with Topotecan + Cyclophosphamide","longName":"5678514v1.00","preferredDefinition":"Induction Cycle 1 with Topotecan + Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49789382-4AA4-226F-E053-F662850A230E","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-27","modifiedBy":"KUMMEROA","dateModified":"2024-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"49789382-4ABD-226F-E053-F662850A230E","beginDate":"2017-02-27","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-27","modifiedBy":"ONEDATA","dateModified":"2017-02-27","deletedIndicator":"No"},{"value":"BEP","valueDescription":"BEP","ValueMeaning":{"publicId":"5629321","version":"1","preferredName":"BEP","longName":"5629321","preferredDefinition":"BEP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46636149-2728-21C1-E053-F662850ACCB4","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46636149-2741-21C1-E053-F662850ACCB4","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"ONEDATA","dateModified":"2017-01-18","deletedIndicator":"No"},{"value":"BEC","valueDescription":"BEC","ValueMeaning":{"publicId":"5629322","version":"1","preferredName":"BEC","longName":"5629322","preferredDefinition":"BEC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46636149-274B-21C1-E053-F662850ACCB4","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46636149-2764-21C1-E053-F662850ACCB4","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"ONEDATA","dateModified":"2017-01-18","deletedIndicator":"No"},{"value":"PEb","valueDescription":"PEb","ValueMeaning":{"publicId":"5629323","version":"1","preferredName":"PEb","longName":"5629323","preferredDefinition":"PEb","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46636149-276E-21C1-E053-F662850ACCB4","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46636149-2787-21C1-E053-F662850ACCB4","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"ONEDATA","dateModified":"2017-01-18","deletedIndicator":"No"},{"value":"CEb","valueDescription":"CEb","ValueMeaning":{"publicId":"5629324","version":"1","preferredName":"CEb","longName":"5629324","preferredDefinition":"CEb","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46636149-2791-21C1-E053-F662850ACCB4","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46636149-27AA-21C1-E053-F662850ACCB4","beginDate":"2017-01-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-01-18","modifiedBy":"ONEDATA","dateModified":"2017-01-18","deletedIndicator":"No"},{"value":"No Treatment","valueDescription":"No treatment","ValueMeaning":{"publicId":"2582115","version":"1","preferredName":"No treatment","longName":"2582115","preferredDefinition":"No treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DD0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-11-22","modifiedBy":"ALAIS","dateModified":"2006-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A6327A8-6584-12D3-E053-F662850AA11C","beginDate":"2017-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2017-03-10","modifiedBy":"ONEDATA","dateModified":"2017-03-10","deletedIndicator":"No"},{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-75C4-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"LBP","valueDescription":"LBP","ValueMeaning":{"publicId":"5678509","version":"1","preferredName":"LBP","longName":"5678509","preferredDefinition":"LBP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-75CE-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4974E0F8-75E7-3829-E053-F662850A7949","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"AALL1631 Arm A","valueDescription":"Arm A","ValueMeaning":{"publicId":"5644354","version":"1","preferredName":"Arm A","longName":"5644354","preferredDefinition":"Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C27-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt SN added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476016AB-8C3F-06A9-E053-F662850A1272","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"AALL1631 Arm HR","valueDescription":"High Risk Arm","ValueMeaning":{"publicId":"5644352","version":"1","preferredName":"High Risk Arm","longName":"5644352","preferredDefinition":"High Risk Arm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8BE2-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476016AB-8BFB-06A9-E053-F662850A1272","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"AALL1631 Arm B","valueDescription":"Arm B","ValueMeaning":{"publicId":"5644353","version":"1","preferredName":"Arm B","longName":"5644353","preferredDefinition":"Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C05-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt VM Named added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476016AB-8C1D-06A9-E053-F662850A1272","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"ANBL1531 Treatment 10","valueDescription":"Induction Cycle 1 with Topotecan + Cyclophosphamide","ValueMeaning":{"publicId":"5858030","version":"1","preferredName":"Induction Cycle 1 with Topotecan + Cyclophosphamide","longName":"5858030","preferredDefinition":"Induction Cycle 1 with Topotecan + Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"514FF5F4-2D6D-1413-E053-F662850AE057","latestVersionIndicator":"Yes","beginDate":"2017-06-06","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"514FF5F4-2D85-1413-E053-F662850AE057","beginDate":"2017-06-06","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-06-06","modifiedBy":"ONEDATA","dateModified":"2017-06-06","deletedIndicator":"No"},{"value":"RT + Surgery","valueDescription":"Radiation Therapy And Surgical Procedure","ValueMeaning":{"publicId":"5829926","version":"1","preferredName":"Radiation Therapy And Surgical Procedure","longName":"5829926","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBC1684-E588-11BA-E053-F662850A9703","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBC1684-E5A1-11BA-E053-F662850A9703","beginDate":"2017-05-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"AMG 232 + RT+ Surgery","valueDescription":"MDM2 Inhibitor AMG-232 And Radiation Therapy And Surgical Procedure","ValueMeaning":{"publicId":"5829925","version":"1","preferredName":"MDM2 Inhibitor AMG-232 And Radiation Therapy And Surgical Procedure","longName":"5829925","preferredDefinition":"An orally available, piperidinone inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor AMG-232 binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Navtemadlin","conceptCode":"C116624","definition":"An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBC1684-E561-11BA-E053-F662850A9703","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4FBC1684-E57A-11BA-E053-F662850A9703","beginDate":"2017-05-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-17","modifiedBy":"ONEDATA","dateModified":"2017-05-17","deletedIndicator":"No"},{"value":"AOST1421 Treatment 2","valueDescription":"Infusion Procedure Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"5839320","version":"1","preferredName":"Infusion Procedure Monoclonal Antibody Ch14.18","longName":"5839320","preferredDefinition":"A method of putting fluids, including drugs, into the bloodstream.: A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infusion Procedure","conceptCode":"C15388","definition":"Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50756899-AB6D-03A0-E053-F662850AF674","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"50756899-AB88-03A0-E053-F662850AF674","beginDate":"2017-05-26","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-05-26","modifiedBy":"ONEDATA","dateModified":"2017-05-26","deletedIndicator":"No"},{"value":"ADVL1521 Treatment","valueDescription":"Trametinib 0.025mg/kg/dose","ValueMeaning":{"publicId":"5741897","version":"1","preferredName":"Trametinib 0.025mg/kg/dose","longName":"5741897","preferredDefinition":"Trametinib 0.025mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C96B50F-1B73-3907-E053-F662850A4731","latestVersionIndicator":"Yes","beginDate":"2017-04-07","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4C96B50F-1B8C-3907-E053-F662850A4731","beginDate":"2017-04-07","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-07","modifiedBy":"ONEDATA","dateModified":"2017-04-07","deletedIndicator":"No"},{"value":"ANBL1531 Arm E","valueDescription":"ANBL1531 Arm E","ValueMeaning":{"publicId":"5783163","version":"1","preferredName":"ANBL1531 Arm E","longName":"5783163","preferredDefinition":"ANBL1531 Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2889DF-D0C6-1A9F-E053-F662850AC452","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E2889DF-D0E1-1A9F-E053-F662850AC452","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"ANBL1531 Arm D","valueDescription":"ANBL1531 Arm D","ValueMeaning":{"publicId":"5783164","version":"1","preferredName":"ANBL1531 Arm D","longName":"5783164","preferredDefinition":"ANBL1531 Arm D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2889DF-D0EB-1A9F-E053-F662850AC452","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E2889DF-D106-1A9F-E053-F662850AC452","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"ANBL1531 Arm C","valueDescription":"ANBL1531 Arm C","ValueMeaning":{"publicId":"5783165","version":"1","preferredName":"ANBL1531 Arm C","longName":"5783165","preferredDefinition":"ANBL1531 Arm C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2889DF-D110-1A9F-E053-F662850AC452","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E2889DF-D12B-1A9F-E053-F662850AC452","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"ANBL1531 Arm B","valueDescription":"ANBL1531 Arm B","ValueMeaning":{"publicId":"5783166","version":"1","preferredName":"ANBL1531 Arm B","longName":"5783166","preferredDefinition":"ANBL1531 Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2889DF-D135-1A9F-E053-F662850AC452","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E2889DF-D150-1A9F-E053-F662850AC452","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"ANBL1531 Arm A","valueDescription":"ANBL1531 Arm A","ValueMeaning":{"publicId":"5783167","version":"1","preferredName":"ANBL1531 Arm A","longName":"5783167","preferredDefinition":"ANBL1531 Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E2889DF-D15A-1A9F-E053-F662850AC452","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E2889DF-D175-1A9F-E053-F662850AC452","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"Blinded product","valueDescription":"Blinded Product","ValueMeaning":{"publicId":"5921519","version":"1","preferredName":"Blinded Product","longName":"5921519","preferredDefinition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.: The end result of a manufacturing process; anything that is produced.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded","conceptCode":"C49068","definition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56CCA5A6-38C3-01A8-E053-F662850A9137","latestVersionIndicator":"Yes","beginDate":"2017-08-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56CCA5A6-38DC-01A8-E053-F662850A9137","beginDate":"2017-08-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-08-15","modifiedBy":"ONEDATA","dateModified":"2017-08-15","deletedIndicator":"No"},{"value":"AHEP1531 Group A2","valueDescription":"Group A2: CDDP 21-days","ValueMeaning":{"publicId":"6080687","version":"1","preferredName":"Group A2: CDDP 21-days","longName":"6080687","preferredDefinition":"AHEP1531 Group A2: CDDP 21-days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65E8AB64-FDAF-154A-E053-F662850A9CC7","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65E8AB64-FDC8-154A-E053-F662850A9CC7","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"AHEP1531 Group A1","valueDescription":"Group A1: Observation","ValueMeaning":{"publicId":"6080688","version":"1","preferredName":"Group A1: Observation","longName":"6080688","preferredDefinition":"AHEP1531 Group A1: Observation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65E8AB64-FDD2-154A-E053-F662850A9CC7","latestVersionIndicator":"Yes","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65E8AB64-FDEB-154A-E053-F662850A9CC7","beginDate":"2018-02-23","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-23","modifiedBy":"ONEDATA","dateModified":"2018-02-23","deletedIndicator":"No"},{"value":"AHEP1531 Group C: C5VD","valueDescription":"Group C: Arm C5VD","ValueMeaning":{"publicId":"6078451","version":"1","preferredName":"Group C: Arm C5VD","longName":"6078451","preferredDefinition":"AHEP1531 Group C: Arm C5VD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-11E4-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"686B409C-7FFA-78A7-E053-F662850A1589","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"AHEP1531 Group E2","valueDescription":"Group E2: PLADO","ValueMeaning":{"publicId":"6078445","version":"1","preferredName":"Group E2: PLADO","longName":"6078445","preferredDefinition":"AHEP1531 Group E2: PLADO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1112-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-112B-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group E1","valueDescription":"Group E1: Observation","ValueMeaning":{"publicId":"6078446","version":"1","preferredName":"Group E1: Observation","longName":"6078446","preferredDefinition":"AHEP1531 Group E1: Observation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1135-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-114E-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group D2: Arm VI","valueDescription":"Group D2: Arm VI","ValueMeaning":{"publicId":"6078447","version":"1","preferredName":"Group D2: Arm VI","longName":"6078447","preferredDefinition":"AHEP1531 Group D2: Arm VI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1158-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-1171-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group D2: Arm CE","valueDescription":"Group D2: Arm CE","ValueMeaning":{"publicId":"6078448","version":"1","preferredName":"Group D2: Arm CE","longName":"6078448","preferredDefinition":"AHEP1531 Group D2: Arm CE","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-117B-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-1194-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group D1","valueDescription":"Group D1: CD","ValueMeaning":{"publicId":"6078449","version":"1","preferredName":"Group D1: CD","longName":"6078449","preferredDefinition":"AHEP1531 Group D1: CD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-119E-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-11B7-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group D","valueDescription":"Group D: SIOPEL-4 Induction (Blocks 1-3)","ValueMeaning":{"publicId":"6078450","version":"1","preferredName":"Group D: SIOPEL-4 Induction (Blocks 1-3)","longName":"6078450","preferredDefinition":"AHEP1531 Group D: SIOPEL-4 Induction (Blocks 1-3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-11C1-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-11DA-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group B2","valueDescription":"Group B2: CDDP 14 days","ValueMeaning":{"publicId":"6078453","version":"1","preferredName":"Group B2: CDDP 14 days","longName":"6078453","preferredDefinition":"AHEP1531 Group B2: CDDP 14 days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-122A-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-1243-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group B1: Arm 6","valueDescription":"Group B1: Arm 6-CDDP (4 Additional Cycles)","ValueMeaning":{"publicId":"6078454","version":"1","preferredName":"Group B1: Arm 6-CDDP (4 Additional Cycles)","longName":"6078454","preferredDefinition":"AHEP1531 Group B1: Arm 6-CDDP (4 Additional Cycles)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-124D-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-1266-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group B1: Arm 4","valueDescription":"Group B1: Arm 4-CDDP (2 Additional Cycles)","ValueMeaning":{"publicId":"6078455","version":"1","preferredName":"Group B1: Arm 4-CDDP (2 Additional Cycles)","longName":"6078455","preferredDefinition":"AHEP1531 Group B1: Arm 4-CDDP (2 Additional Cycles)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1270-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-1289-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group B","valueDescription":"Group B: CDDP 14-days","ValueMeaning":{"publicId":"6078456","version":"1","preferredName":"Group B: CDDP 14-days","longName":"6078456","preferredDefinition":"AHEP1531 Group B: CDDP 14-days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1293-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-12AC-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"AHEP1531 Group A","valueDescription":"Group A: Rapid Pathology Review","ValueMeaning":{"publicId":"6078457","version":"1","preferredName":"Group A: Rapid Pathology Review","longName":"6078457","preferredDefinition":"AHEP1531 Group A: Rapid Pathology Review","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-12B6-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65D58E2D-12CF-3121-E053-F662850A64E2","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","deletedIndicator":"No"},{"value":"Kit #102","valueDescription":"Kit #102","ValueMeaning":{"publicId":"6045017","version":"1","preferredName":"Kit #102","longName":"6045017","preferredDefinition":"A blinded study product identifier to allow for blinded product distribution by a centralized pharmacy to patient-enrolling clinical sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6141E8D7-1269-74F7-E053-F662850A805E","latestVersionIndicator":"Yes","beginDate":"2017-12-26","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6141E8D7-1282-74F7-E053-F662850A805E","beginDate":"2017-12-26","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-26","modifiedBy":"ONEDATA","dateModified":"2017-12-26","deletedIndicator":"No"},{"value":"Kit #101","valueDescription":"Kit #101","ValueMeaning":{"publicId":"6045018","version":"1","preferredName":"Kit #101","longName":"6045018","preferredDefinition":"A blinded study product identifier to allow for blinded product distribution by a centralized pharmacy to patient-enrolling clinical sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6141E8D7-128C-74F7-E053-F662850A805E","latestVersionIndicator":"Yes","beginDate":"2017-12-26","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6141E8D7-12A5-74F7-E053-F662850A805E","beginDate":"2017-12-26","endDate":null,"createdBy":"HAMMA","dateCreated":"2017-12-26","modifiedBy":"ONEDATA","dateModified":"2017-12-26","deletedIndicator":"No"},{"value":"AHEP1531 Group C: CDDP","valueDescription":"Group C: Arm CDDP","ValueMeaning":{"publicId":"6078452","version":"1","preferredName":"Group C: Arm CDDP","longName":"6078452","preferredDefinition":"AHEP1531 Group C: Arm CDDP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-1207-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"686A0E5E-D154-3693-E053-F662850A3C3A","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"AHEP1531 Group F: PLADO","valueDescription":"Group F: Arm PLADO","ValueMeaning":{"publicId":"6078444","version":"1","preferredName":"Group F: Arm PLADO","longName":"6078444","preferredDefinition":"AHEP1531 Group F: Arm PLADO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-10EF-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"686A0E5E-D168-3693-E053-F662850A3C3A","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"AHEP1531 Group F: P/GEMOX","valueDescription":"Group F: Arm PLADO/GEMOX","ValueMeaning":{"publicId":"6078443","version":"1","preferredName":"Group F: Arm PLADO/GEMOX","longName":"6078443","preferredDefinition":"AHEP1531 Group F: Arm PLADO/GEMOX","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65D58E2D-10CC-3121-E053-F662850A64E2","latestVersionIndicator":"Yes","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-02-22","modifiedBy":"ONEDATA","dateModified":"2018-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"686A0E5E-D17C-3693-E053-F662850A3C3A","beginDate":"2018-02-22","endDate":null,"createdBy":"HLAINGY","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"ADVL1521 Treatment","valueDescription":"Trametinib 0.032 mg/kg/dose","ValueMeaning":{"publicId":"6361742","version":"1","preferredName":"Trametinib 0.032 mg/kg/dose","longName":"6361742","preferredDefinition":"Trametinib 0.032 mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"715F21E1-88A0-7309-E053-F662850A6438","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"715F21E1-88B9-7309-E053-F662850A6438","beginDate":"2018-07-19","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","deletedIndicator":"No"},{"value":"AREN1721 Arm C","valueDescription":"Arm C","ValueMeaning":{"publicId":"2683536","version":"1","preferredName":"Arm C","longName":"2683536","preferredDefinition":"Arm C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAA63E8-3CE8-67CA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71D39E95-3F5B-12B2-E053-F662850A6E8F","beginDate":"2018-07-25","endDate":null,"createdBy":"LEEW","dateCreated":"2018-07-25","modifiedBy":"ONEDATA","dateModified":"2018-07-25","deletedIndicator":"No"},{"value":"AREN1721 Arm B","valueDescription":"Arm B","ValueMeaning":{"publicId":"5644353","version":"1","preferredName":"Arm B","longName":"5644353","preferredDefinition":"Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C05-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt VM Named added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71D39E95-3F6F-12B2-E053-F662850A6E8F","beginDate":"2018-07-25","endDate":null,"createdBy":"LEEW","dateCreated":"2018-07-25","modifiedBy":"ONEDATA","dateModified":"2018-07-25","deletedIndicator":"No"},{"value":"AREN1721 Arm A","valueDescription":"Arm A","ValueMeaning":{"publicId":"5644354","version":"1","preferredName":"Arm A","longName":"5644354","preferredDefinition":"Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C27-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt SN added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71D39E95-3F83-12B2-E053-F662850A6E8F","beginDate":"2018-07-25","endDate":null,"createdBy":"LEEW","dateCreated":"2018-07-25","modifiedBy":"ONEDATA","dateModified":"2018-07-25","deletedIndicator":"No"},{"value":"Trametinib 0.032 mg/kg/dose","valueDescription":"Trametinib 0.032 mg/kg/dose","ValueMeaning":{"publicId":"6361742","version":"1","preferredName":"Trametinib 0.032 mg/kg/dose","longName":"6361742","preferredDefinition":"Trametinib 0.032 mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"715F21E1-88A0-7309-E053-F662850A6438","latestVersionIndicator":"Yes","beginDate":"2018-07-19","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-07-19","modifiedBy":"ONEDATA","dateModified":"2018-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71734A95-26E8-2847-E053-F662850AE8C9","beginDate":"2018-07-20","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-07-20","modifiedBy":"ONEDATA","dateModified":"2018-07-20","deletedIndicator":"No"},{"value":"Trametinib 0.025mg/kg/dose","valueDescription":"Trametinib 0.025mg/kg/dose","ValueMeaning":{"publicId":"5741897","version":"1","preferredName":"Trametinib 0.025mg/kg/dose","longName":"5741897","preferredDefinition":"Trametinib 0.025mg/kg/dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C96B50F-1B73-3907-E053-F662850A4731","latestVersionIndicator":"Yes","beginDate":"2017-04-07","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71734A95-26FC-2847-E053-F662850AE8C9","beginDate":"2018-07-20","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-07-20","modifiedBy":"ONEDATA","dateModified":"2018-07-20","deletedIndicator":"No"},{"value":"Chemo RT then Maint Chemo","valueDescription":"Chemo RT then Maint Chemo","ValueMeaning":{"publicId":"6346892","version":"1","preferredName":"Chemo RT then Maint Chemo","longName":"6346892","preferredDefinition":"Chemo RT then Maint Chemo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7057ABA7-6BD8-49E7-E053-F662850AD91A","latestVersionIndicator":"Yes","beginDate":"2018-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-06","modifiedBy":"ONEDATA","dateModified":"2018-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7057ABA7-6BF1-49E7-E053-F662850AD91A","beginDate":"2018-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-06","modifiedBy":"ONEDATA","dateModified":"2018-07-06","deletedIndicator":"No"},{"value":"ANBL17P1 Treatment","valueDescription":"Induction with Ch14.18 and GM-CSF","ValueMeaning":{"publicId":"6548039","version":"1","preferredName":"Induction with Ch14.18 and GM-CSF","longName":"6548039","preferredDefinition":"Induction with Dinutuximab (Ch14.18) and Sargramostim (GM-CSF)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79F22646-73BF-55BB-E053-F662850A2599","latestVersionIndicator":"Yes","beginDate":"2018-11-05","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"79F22646-73D8-55BB-E053-F662850A2599","beginDate":"2018-11-05","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","deletedIndicator":"No"},{"value":"Discontinuation of TKI","valueDescription":"Discontinuation of TKI","ValueMeaning":{"publicId":"6547745","version":"1","preferredName":"Discontinuation of TKI","longName":"6547745","preferredDefinition":"Discontinuation of TKI","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"79EDBCD0-1EEE-1790-E053-F662850A3670","latestVersionIndicator":"Yes","beginDate":"2018-11-05","endDate":null,"createdBy":"LEEW","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"79EDBCD0-1F07-1790-E053-F662850A3670","beginDate":"2018-11-05","endDate":null,"createdBy":"LEEW","dateCreated":"2018-11-05","modifiedBy":"ONEDATA","dateModified":"2018-11-05","deletedIndicator":"No"},{"value":"ANBL1821 Regimen A","valueDescription":"ANBL1821 Regimen A","ValueMeaning":{"publicId":"6615016","version":"1","preferredName":"ANBL1821 Regimen A","longName":"6615016","preferredDefinition":"Regimen A: Dinutuximab, Irinotecan, Temozolomide, and Sargramostim (GMCSF)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F9A9A3C-6B80-755C-E053-F662850AECDD","latestVersionIndicator":"Yes","beginDate":"2019-01-16","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-16","modifiedBy":"ONEDATA","dateModified":"2019-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F9A9A3C-6B99-755C-E053-F662850AECDD","beginDate":"2019-01-16","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-16","modifiedBy":"ONEDATA","dateModified":"2019-01-16","deletedIndicator":"No"},{"value":"ANBL1821 Regimen B","valueDescription":"ANBL1821 Regimen B","ValueMeaning":{"publicId":"6615015","version":"1","preferredName":"ANBL1821 Regimen B","longName":"6615015","preferredDefinition":"Regimen B: Dinutuximab, Irinotecan, Temozolomide, Sargramostim (GMCSF), and Eflornithine (DFMO)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F9A9A3C-6B5D-755C-E053-F662850AECDD","latestVersionIndicator":"Yes","beginDate":"2019-01-16","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-16","modifiedBy":"ONEDATA","dateModified":"2019-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F9A9A3C-6B76-755C-E053-F662850AECDD","beginDate":"2019-01-16","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-16","modifiedBy":"ONEDATA","dateModified":"2019-01-16","deletedIndicator":"No"},{"value":"ANHL1522 Treatment 40","valueDescription":"Course LMP-TC2","ValueMeaning":{"publicId":"5508283","version":"1","preferredName":"Course LMP-TC2","longName":"5508283","preferredDefinition":"Course LMP-TC2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4F6A65-E0AF-5D5F-E053-F662850A5C3C","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"CHANGP","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F39010B-2DFA-1198-E053-F662850AAC93","beginDate":"2019-01-11","endDate":null,"createdBy":"GALITG","dateCreated":"2019-01-11","modifiedBy":"ONEDATA","dateModified":"2019-01-11","deletedIndicator":"No"},{"value":"Arm AC DL1","valueDescription":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","ValueMeaning":{"publicId":"7236092","version":"1","preferredName":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","longName":"7236092","preferredDefinition":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-990B-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A25189D3-861C-699B-E053-F662850AAC83","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm A","valueDescription":"Arm A: Standard Chemotherapy (DA + GO)","ValueMeaning":{"publicId":"7236094","version":"1","preferredName":"Arm A: Standard Chemotherapy (DA + GO)","longName":"7236094","preferredDefinition":"Arm A: Standard Chemotherapy (DA + GO)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-9951-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2694C6E-C616-39E3-E053-F662850A409D","beginDate":"2020-04-03","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-03","modifiedBy":"ONEDATA","dateModified":"2020-04-03","deletedIndicator":"No"},{"value":"Arm B","valueDescription":"Arm B: CPX-351 + GO","ValueMeaning":{"publicId":"7236093","version":"1","preferredName":"Arm B: CPX-351 + GO","longName":"7236093","preferredDefinition":"Arm B: CPX-351 + GO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-992E-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2694C6E-C602-39E3-E053-F662850A409D","beginDate":"2020-04-03","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-03","modifiedBy":"ONEDATA","dateModified":"2020-04-03","deletedIndicator":"No"},{"value":"Arm D Post-Consolidation","valueDescription":"Arm D Post-Consolidation","ValueMeaning":{"publicId":"6691103","version":"1","preferredName":"Arm D Post-Consolidation","longName":"6691103","preferredDefinition":"Arm D Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865B89CE-B4A6-5E01-E053-F662850A140B","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"865B89CE-B4BF-5E01-E053-F662850A140B","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Arm C Post-Consolidation","valueDescription":"Arm C Post-Consolidation","ValueMeaning":{"publicId":"6691104","version":"1","preferredName":"Arm C Post-Consolidation","longName":"6691104","preferredDefinition":"Arm C Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865B89CE-B4C9-5E01-E053-F662850A140B","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"865B89CE-B4E2-5E01-E053-F662850A140B","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Arm B Post-Consolidation","valueDescription":"Arm B Post-Consolidation","ValueMeaning":{"publicId":"6691105","version":"1","preferredName":"Arm B Post-Consolidation","longName":"6691105","preferredDefinition":"Arm B Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865B89CE-B4EC-5E01-E053-F662850A140B","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"865B89CE-B505-5E01-E053-F662850A140B","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Arm A Post-Consolidation","valueDescription":"Arm A Post-Consolidation","ValueMeaning":{"publicId":"6691106","version":"1","preferredName":"Arm A Post-Consolidation","longName":"6691106","preferredDefinition":"Arm A Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865B89CE-B50F-5E01-E053-F662850A140B","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"865B89CE-B528-5E01-E053-F662850A140B","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"DS-HIGH Post Induction","valueDescription":"DS-HIGH Post Induction","ValueMeaning":{"publicId":"6691120","version":"1","preferredName":"DS-HIGH Post Induction","longName":"6691120","preferredDefinition":"DS-HIGH Post Induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8659914D-F0D9-7604-E053-F662850ABF57","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8659914D-F0F2-7604-E053-F662850ABF57","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"SR Consolidation","valueDescription":"SR Consolidation","ValueMeaning":{"publicId":"6691122","version":"1","preferredName":"SR Consolidation","longName":"6691122","preferredDefinition":"SR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8659914D-F11F-7604-E053-F662850ABF57","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8659914D-F138-7604-E053-F662850ABF57","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"SR-FAV Post-Induction","valueDescription":"SR-FAV Post-Induction","ValueMeaning":{"publicId":"6691123","version":"1","preferredName":"SR-FAV Post-Induction","longName":"6691123","preferredDefinition":"SR-FAV Post-Induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8659914D-F142-7604-E053-F662850ABF57","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8659914D-F15B-7604-E053-F662850ABF57","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"SR-HIGH: Arm D Therapy","valueDescription":"SR-HIGH: Arm D Therapy","ValueMeaning":{"publicId":"6689974","version":"1","preferredName":"SR-HIGH: Arm D Therapy","longName":"6689974","preferredDefinition":"SR-HIGH: Arm D Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8644B35D-A366-479A-E053-F662850A762A","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8644B35D-A37F-479A-E053-F662850A762A","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","deletedIndicator":"No"},{"value":"SR-HIGH: Arm C Therapy","valueDescription":"SR-HIGH: Arm C Therapy","ValueMeaning":{"publicId":"6689975","version":"1","preferredName":"SR-HIGH: Arm C Therapy","longName":"6689975","preferredDefinition":"SR-HIGH: Arm C Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8644B35D-A389-479A-E053-F662850A762A","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8644B35D-A3A2-479A-E053-F662850A762A","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","deletedIndicator":"No"},{"value":"SR-AVG: Arm B Therapy","valueDescription":"SR-AVG: Arm B Therapy","ValueMeaning":{"publicId":"6689976","version":"1","preferredName":"SR-AVG: Arm B Therapy","longName":"6689976","preferredDefinition":"SR-AVG: Arm B Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8644B35D-A3AC-479A-E053-F662850A762A","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8644B35D-A3C5-479A-E053-F662850A762A","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","deletedIndicator":"No"},{"value":"SR-AVG: Arm A Therapy","valueDescription":"SR-AVG: Arm A Therapy","ValueMeaning":{"publicId":"6689977","version":"1","preferredName":"SR-AVG: Arm A Therapy","longName":"6689977","preferredDefinition":"SR-AVG: Arm A Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8644B35D-A3CF-479A-E053-F662850A762A","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8644B35D-A3E8-479A-E053-F662850A762A","beginDate":"2019-04-11","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-11","modifiedBy":"ONEDATA","dateModified":"2019-04-11","deletedIndicator":"No"},{"value":"20: B-LLy All therapy","valueDescription":"B-LLy  All therapy","ValueMeaning":{"publicId":"6686903","version":"1","preferredName":"B-LLy - All therapy","longName":"6686903v1.00","preferredDefinition":"AALL1731 B-LLy - All therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CC15BC-4934-06AF-E053-F662850ABA88","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-05","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CC15BC-494D-06AF-E053-F662850ABA88","beginDate":"2019-04-05","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"10: B-ALL Induction only","valueDescription":"B-ALL  Induction therapy only","ValueMeaning":{"publicId":"6686904","version":"1","preferredName":"B-ALL - Induction therapy only","longName":"6686904v1.00","preferredDefinition":"AALL1731 B-ALL - Induction therapy only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CC15BC-4957-06AF-E053-F662850ABA88","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-05","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CC15BC-4970-06AF-E053-F662850ABA88","beginDate":"2019-04-05","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"Tx 60: DS-HIGH B-ALL - All Post Induction Therapy","valueDescription":"Tx 60: DS-HIGH B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6685633","version":"1","preferredName":"Tx 60: DS-HIGH B-ALL - All Post Induction Therapy","longName":"6685633","preferredDefinition":"AALL1731 Treatment Assignment 60: DS-High B-ALL- All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85951B29-F5EE-0FE7-E053-F662850AAAA8","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85951B29-F607-0FE7-E053-F662850AAAA8","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","deletedIndicator":"No"},{"value":"Tx 50: SR-HIGH B-ALL - HR Consolidation","valueDescription":"Tx 50: SR-HIGH B-ALL - HR Consolidation","ValueMeaning":{"publicId":"6685634","version":"1","preferredName":"Tx 50: SR-HIGH B-ALL - HR Consolidation","longName":"6685634","preferredDefinition":"AALL1731 Treatment Assignment 50: SR-High B-ALL- HR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85951B29-F611-0FE7-E053-F662850AAAA8","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85951B29-F62A-0FE7-E053-F662850AAAA8","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","deletedIndicator":"No"},{"value":"Tx 40: SR-AVG B-ALL - SR Consolidation","valueDescription":"Tx 40: SR-AVG B-ALL - SR Consolidation","ValueMeaning":{"publicId":"6685635","version":"1","preferredName":"Tx 40: SR-AVG B-ALL - SR Consolidation","longName":"6685635","preferredDefinition":"AALL1731 Treatment Assignment 40: SR-Average B-ALL- SR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85951B29-F634-0FE7-E053-F662850AAAA8","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85951B29-F64D-0FE7-E053-F662850AAAA8","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","deletedIndicator":"No"},{"value":"Tx 30: SR-FAV B-ALL - All Post Induction Therapy","valueDescription":"Tx 30: SR-FAV B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6685636","version":"1","preferredName":"Tx 30: SR-FAV B-ALL - All Post Induction Therapy","longName":"6685636","preferredDefinition":"AALL1731 Treatment Assignment 30: SR-Favorable B-ALL- All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85951B29-F657-0FE7-E053-F662850AAAA8","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85951B29-F670-0FE7-E053-F662850AAAA8","beginDate":"2019-04-02","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-02","modifiedBy":"ONEDATA","dateModified":"2019-04-02","deletedIndicator":"No"},{"value":"60: DS-HIGH Post Induct.","valueDescription":"DS-HIGH B-ALL  All Post Induction Therapy","ValueMeaning":{"publicId":"6688465","version":"1","preferredName":"DS-HIGH B-ALL - All Post Induction Therapy","longName":"6688465v1.00","preferredDefinition":"AALL1731 DS-HIGH B-ALL - All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BF0AB-141E-1F90-E053-F662850AEBDA","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860BF0AB-1437-1F90-E053-F662850AEBDA","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"50: SR-AVG HR Consol.","valueDescription":"SR-HIGH B-ALL  HR Consolidation","ValueMeaning":{"publicId":"6688466","version":"1","preferredName":"SR-HIGH B-ALL - HR Consolidation","longName":"6688466v1.00","preferredDefinition":"AALL1731 SR-HIGH B-ALL - HR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BF0AB-1441-1F90-E053-F662850AEBDA","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860BF0AB-145A-1F90-E053-F662850AEBDA","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"40: SR-AVG SR Consol.","valueDescription":"SR-AVG B-ALL  SR Consolidation","ValueMeaning":{"publicId":"6688467","version":"1","preferredName":"SR-AVG B-ALL - SR Consolidation","longName":"6688467v1.00","preferredDefinition":"AALL1731 SR-AVG B-ALL - SR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BF0AB-1464-1F90-E053-F662850AEBDA","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860BF0AB-147D-1F90-E053-F662850AEBDA","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"30: SR-FAV Post Induct.","valueDescription":"SR-FAV B-ALL- All Post Induction Therapy","ValueMeaning":{"publicId":"6688468","version":"1","preferredName":"SR-FAV B-ALL- All Post Induction Therapy","longName":"6688468","preferredDefinition":"AALL1731 SR-FAV B-ALL- All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BF0AB-1487-1F90-E053-F662850AEBDA","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860BF0AB-14A0-1F90-E053-F662850AEBDA","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"},{"value":"ADVL1823 LOXO-101C","valueDescription":"Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course with intrathecal MTX or ARAC or MTX/HC/ARAC","ValueMeaning":{"publicId":"6662794","version":"1","preferredName":"Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course with intrathecal MTX or ARAC or MTX/HC/ARAC","longName":"6662794","preferredDefinition":"ADVL1823 LOXO-101C: Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course with intrathecal MTX or ARAC or MTX/HC/ARAC","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8386AD5A-E9D9-0381-E053-F662850A598A","latestVersionIndicator":"Yes","beginDate":"2019-03-07","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8386AD5A-E9F2-0381-E053-F662850A598A","beginDate":"2019-03-07","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","deletedIndicator":"No"},{"value":"ADVL1823 LOXO-101","valueDescription":"Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course","ValueMeaning":{"publicId":"6662795","version":"1","preferredName":"Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course","longName":"6662795","preferredDefinition":"ADVL1823 LOXO-101: Larotrectinib 100 mg/m2/dose orally/NG/G-tube twice daily over a 28 day course","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8386AD5A-E9FC-0381-E053-F662850A598A","latestVersionIndicator":"Yes","beginDate":"2019-03-07","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8386AD5A-EA15-0381-E053-F662850A598A","beginDate":"2019-03-07","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","deletedIndicator":"No"},{"value":"Arm 2 Selumetinib","valueDescription":"Arm 2 Selumetinib","ValueMeaning":{"publicId":"6664982","version":"1","preferredName":"Arm 2 Selumetinib","longName":"6664982","preferredDefinition":"Arm 2 Selumetinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D48076-3E35-7AAC-E053-F662850A3104","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-11","modifiedBy":"ONEDATA","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83D48076-3E4E-7AAC-E053-F662850A3104","beginDate":"2019-03-11","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-11","modifiedBy":"ONEDATA","dateModified":"2019-03-11","deletedIndicator":"No"},{"value":"Arm 1 CV","valueDescription":"Arm 1 CV","ValueMeaning":{"publicId":"6664983","version":"1","preferredName":"Arm 1 CV","longName":"6664983","preferredDefinition":"Arm 1 Carboplatin/Vincristine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D48076-3E58-7AAC-E053-F662850A3104","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-11","modifiedBy":"ONEDATA","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83D48076-3E71-7AAC-E053-F662850A3104","beginDate":"2019-03-11","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-03-11","modifiedBy":"ONEDATA","dateModified":"2019-03-11","deletedIndicator":"No"},{"value":"DS-HIGH Post Induction","valueDescription":"60: DS-HIGH B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6730265","version":"1","preferredName":"60: DS-HIGH B-ALL - All Post Induction Therapy","longName":"6730265","preferredDefinition":"60: DS-HIGH B-ALL - All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC2C-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BC45-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"SR Consolidation","valueDescription":"40: SR-AVG B-ALL - SR Consolidation","ValueMeaning":{"publicId":"6730267","version":"1","preferredName":"40: SR-AVG B-ALL - SR Consolidation","longName":"6730267","preferredDefinition":"40: SR-AVG B-ALL - SR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC72-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BC8B-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"SR-FAV Post-Induction","valueDescription":"30: SR-FAV B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6730268","version":"1","preferredName":"30: SR-FAV B-ALL - All Post Induction Therapy","longName":"6730268","preferredDefinition":"30: SR-FAV B-ALL - All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC95-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BCAE-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"90: Arm D Post-Consolidation","valueDescription":"90: Arm D Post-Consolidation","ValueMeaning":{"publicId":"6730277","version":"1","preferredName":"90: Arm D Post-Consolidation","longName":"6730277","preferredDefinition":"90: Arm D Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BCF9-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BD12-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"80: Arm C Post-Consolidation","valueDescription":"80: Arm C Post-Consolidation","ValueMeaning":{"publicId":"6730278","version":"1","preferredName":"80: Arm C Post-Consolidation","longName":"6730278","preferredDefinition":"80: Arm C Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD1C-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BD35-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"75: Arm B Post-Consolidation","valueDescription":"75: Arm B Post-Consolidation","ValueMeaning":{"publicId":"6730279","version":"1","preferredName":"75: Arm B Post-Consolidation","longName":"6730279","preferredDefinition":"75: Arm B Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD3F-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BD58-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"70: Arm A Post-Consolidation","valueDescription":"70: Arm A Post-Consolidation","ValueMeaning":{"publicId":"6730280","version":"1","preferredName":"70: Arm A Post-Consolidation","longName":"6730280","preferredDefinition":"70: Arm A Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD62-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"874D9F87-BD7B-25B4-E053-F662850AADD7","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","deletedIndicator":"No"},{"value":"AALL1732 Treatment 60","valueDescription":"HR-B-ALL - Arm B Post Consolidation Therapy","ValueMeaning":{"publicId":"6832055","version":"1","preferredName":"HR-B-ALL - Arm B Post Consolidation Therapy","longName":"6832055","preferredDefinition":"HR-B-ALL - Arm B Post Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E8A16CA-C81C-68D5-E053-F662850A542B","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E8A16CA-C835-68D5-E053-F662850A542B","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 50","valueDescription":"HR-B-ALL - Arm A Post Consolidation Therapy","ValueMeaning":{"publicId":"6832056","version":"1","preferredName":"HR-B-ALL - Arm A Post Consolidation Therapy","longName":"6832056","preferredDefinition":"HR-B-ALL - Arm A Post Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E8A16CA-C83F-68D5-E053-F662850A542B","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E8A16CA-C858-68D5-E053-F662850A542B","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 40","valueDescription":"HR-Favorable B-ALL - Post Consolidation Therapy","ValueMeaning":{"publicId":"6832057","version":"1","preferredName":"HR-Favorable B-ALL - Post Consolidation Therapy","longName":"6832057","preferredDefinition":"HR-Favorable B-ALL - Post Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E8A16CA-C862-68D5-E053-F662850A542B","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E8A16CA-C87B-68D5-E053-F662850A542B","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 70","valueDescription":"HR-B-ALL Adherence - IP","ValueMeaning":{"publicId":"6831741","version":"1","preferredName":"HR-B-ALL Adherence - IP","longName":"6831741","preferredDefinition":"HR-B-ALL Adherence - IP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E89F5BE-7FA7-485A-E053-F662850A1892","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E89F5BE-7FC0-485A-E053-F662850A1892","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 90","valueDescription":"HR-B-ALL Adherence - pIP","ValueMeaning":{"publicId":"6831739","version":"1","preferredName":"HR-B-ALL Adherence - pIP","longName":"6831739","preferredDefinition":"HR-B-ALL Adherence - pIP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E89F5BE-7F61-485A-E053-F662850A1892","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E89F5BE-7F7A-485A-E053-F662850A1892","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 80","valueDescription":"HR-B-ALL Adherence - iIP","ValueMeaning":{"publicId":"6831740","version":"1","preferredName":"HR-B-ALL Adherence - iIP","longName":"6831740","preferredDefinition":"HR-B-ALL Adherence - iIP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E89F5BE-7F84-485A-E053-F662850A1892","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E89F5BE-7F9D-485A-E053-F662850A1892","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"AALL1732 Treatment 30","valueDescription":"MPAL Study Therapy","ValueMeaning":{"publicId":"6821801","version":"1","preferredName":"MPAL Study Therapy","longName":"6821801","preferredDefinition":"MPAL Study Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5C9C7B-2FE0-1AB8-E053-F662850A9EAE","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5C9C7B-2FF9-1AB8-E053-F662850A9EAE","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"AALL1732 Treatment 20","valueDescription":"B-LLy Study Therapy","ValueMeaning":{"publicId":"6821802","version":"1","preferredName":"B-LLy Study Therapy","longName":"6821802","preferredDefinition":"B-LLy Study Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5C9C7B-3003-1AB8-E053-F662850A9EAE","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5C9C7B-301C-1AB8-E053-F662850A9EAE","beginDate":"2019-07-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"RT then Maintenance Chemo","valueDescription":"Radiation Therapy Then Maintenance Chemotherapy","ValueMeaning":{"publicId":"6775252","version":"1","preferredName":"Radiation Therapy Then Maintenance Chemotherapy","longName":"6775252","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.: No Value Exists: The act of sustaining something in its current form or proper condition; upkeep.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Then","conceptCode":"C65106","definition":"Occurring at a time in the near future.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Maintenance","conceptCode":"C53297","definition":"The act of sustaining something in its current form or proper condition; upkeep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A9CE42F-C5AF-0B4E-E053-F662850A8740","latestVersionIndicator":"Yes","beginDate":"2019-06-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-06-05","modifiedBy":"HARTLEYG","dateModified":"2019-06-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A9CE42F-C5C8-0B4E-E053-F662850A8740","beginDate":"2019-06-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-06-05","modifiedBy":"ONEDATA","dateModified":"2019-06-05","deletedIndicator":"No"},{"value":"AALL1731 Stratum 30","valueDescription":"SR-FAV B-ALL- All Post Induction Therapy","ValueMeaning":{"publicId":"6688468","version":"1","preferredName":"SR-FAV B-ALL- All Post Induction Therapy","longName":"6688468","preferredDefinition":"AALL1731 SR-FAV B-ALL- All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860BF0AB-1487-1F90-E053-F662850AEBDA","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87646D6E-B6D4-3C26-E053-F662850AC1F3","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AALL1731 Treatment 40","valueDescription":"40: SR-AVG B-ALL - SR Consolidation","ValueMeaning":{"publicId":"6730267","version":"1","preferredName":"40: SR-AVG B-ALL - SR Consolidation","longName":"6730267","preferredDefinition":"40: SR-AVG B-ALL - SR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC72-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89810CA3-1F3B-780B-E053-F662850A117C","beginDate":"2019-05-22","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-05-22","modifiedBy":"ONEDATA","dateModified":"2019-05-22","deletedIndicator":"No"},{"value":"AALL1731 Treatment 20","valueDescription":"20: B-LLy All therapy","ValueMeaning":{"publicId":"6751665","version":"1","preferredName":"20: B-LLy All therapy","longName":"6751665","preferredDefinition":"20: B-LLy All therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8854B791-F1A0-07CC-E053-F662850A009A","latestVersionIndicator":"Yes","beginDate":"2019-05-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-07","modifiedBy":"ONEDATA","dateModified":"2019-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8854B791-F1B9-07CC-E053-F662850A009A","beginDate":"2019-05-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-07","modifiedBy":"ONEDATA","dateModified":"2019-05-07","deletedIndicator":"No"},{"value":"AALL1731 Treatment 10","valueDescription":"10: B-ALL Induction therapy only","ValueMeaning":{"publicId":"6751666","version":"1","preferredName":"10: B-ALL Induction therapy only","longName":"6751666","preferredDefinition":"10: B-ALL Induction therapy only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8854B791-F1C3-07CC-E053-F662850A009A","latestVersionIndicator":"Yes","beginDate":"2019-05-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-07","modifiedBy":"ONEDATA","dateModified":"2019-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8854B791-F1DC-07CC-E053-F662850A009A","beginDate":"2019-05-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-07","modifiedBy":"ONEDATA","dateModified":"2019-05-07","deletedIndicator":"No"},{"value":"AALL1731 Treatment 60","valueDescription":"60: DS-HIGH B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6730265","version":"1","preferredName":"60: DS-HIGH B-ALL - All Post Induction Therapy","longName":"6730265","preferredDefinition":"60: DS-HIGH B-ALL - All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC2C-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8981325D-7A6D-3942-E053-F662850ADCE7","beginDate":"2019-05-22","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-05-22","modifiedBy":"ONEDATA","dateModified":"2019-05-22","deletedIndicator":"No"},{"value":"AALL1731 Treatment 85","valueDescription":"85: Arm D Post-Consolidation","ValueMeaning":{"publicId":"6731705","version":"1","preferredName":"85: Arm D Post-Consolidation","longName":"6731705","preferredDefinition":"85: Arm D Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87642B7D-58FF-025B-E053-F662850ADEAE","latestVersionIndicator":"Yes","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87642B7D-5918-025B-E053-F662850ADEAE","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AALL1731 Treatment 80","valueDescription":"80: Arm C Post-Consolidation","ValueMeaning":{"publicId":"6730278","version":"1","preferredName":"80: Arm C Post-Consolidation","longName":"6730278","preferredDefinition":"80: Arm C Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD1C-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87642B7D-592C-025B-E053-F662850ADEAE","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AALL1731 Treatment 75","valueDescription":"75: Arm B Post-Consolidation","ValueMeaning":{"publicId":"6730279","version":"1","preferredName":"75: Arm B Post-Consolidation","longName":"6730279","preferredDefinition":"75: Arm B Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD3F-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87642B7D-5940-025B-E053-F662850ADEAE","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AALL1731 Treatment 70","valueDescription":"70: Arm A Post-Consolidation","ValueMeaning":{"publicId":"6730280","version":"1","preferredName":"70: Arm A Post-Consolidation","longName":"6730280","preferredDefinition":"70: Arm A Post-Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BD62-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87642B7D-5954-025B-E053-F662850ADEAE","beginDate":"2019-04-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AALL1731 Treatment 50","valueDescription":"50: SR- HIGH B-ALL - HR Consolidation","ValueMeaning":{"publicId":"6780846","version":"1","preferredName":"50: SR- HIGH B-ALL - HR Consolidation","longName":"6780846","preferredDefinition":"50: SR- HIGH B-ALL - HR Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B3724C9-B20F-5A22-E053-F662850ADD95","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-06-13","modifiedBy":"ONEDATA","dateModified":"2019-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B3724C9-B228-5A22-E053-F662850ADD95","beginDate":"2019-06-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-06-13","modifiedBy":"ONEDATA","dateModified":"2019-06-13","deletedIndicator":"No"},{"value":"AALL1732 Treatment 10","valueDescription":"B-ALL Induction/Consolidation Therapy","ValueMeaning":{"publicId":"6831724","version":"1","preferredName":"B-ALL Induction/Consolidation Therapy","longName":"6831724","preferredDefinition":"B-ALL Induction/Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E899791-340A-0922-E053-F662850AEC1F","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"912FB688-1D2F-4D28-E053-F662850A2455","beginDate":"2019-08-28","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-08-28","modifiedBy":"ONEDATA","dateModified":"2019-08-28","deletedIndicator":"No"},{"value":"AALL1731 Treatment 30","valueDescription":"30: SR-FAV B-ALL - All Post Induction Therapy","ValueMeaning":{"publicId":"6730268","version":"1","preferredName":"30: SR-FAV B-ALL - All Post Induction Therapy","longName":"6730268","preferredDefinition":"30: SR-FAV B-ALL - All Post Induction Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"874D9F87-BC95-25B4-E053-F662850AADD7","latestVersionIndicator":"Yes","beginDate":"2019-04-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-24","modifiedBy":"ONEDATA","dateModified":"2019-04-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87AEE066-D460-73B7-E053-F662850A2A20","beginDate":"2019-04-29","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-29","modifiedBy":"ONEDATA","dateModified":"2019-04-29","deletedIndicator":"No"},{"value":"Nirogacestat 90 mg/m2","valueDescription":"Gamma Secretase Inhibitor PF-03084014","ValueMeaning":{"publicId":"3813175","version":"1","preferredName":"Gamma Secretase Inhibitor PF-03084014","longName":"3813175","preferredDefinition":"A selective gamma secretase (GS) inhibitor with potential antitumor activity. Gamma secretase inhibitor PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors; Notch signaling pathway inhibition may follow, which may result in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nirogacestat","conceptCode":"C82383","definition":"A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DC2A43-2B01-EAC1-E040-BB89AD43563F","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA61CC7-4682-0D1B-E053-F662850A57E7","beginDate":"2020-01-08","endDate":null,"createdBy":"DAVISJ","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2020-01-08","deletedIndicator":"No"},{"value":"ADVL18P1 Dose Level 1","valueDescription":"Begin Dose","ValueMeaning":{"publicId":"7090464","version":"1","preferredName":"Begin Dose","longName":"7090464","preferredDefinition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"997505B0-E380-6A24-E053-F662850A7802","latestVersionIndicator":"Yes","beginDate":"2019-12-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"997505B0-E399-6A24-E053-F662850A7802","beginDate":"2019-12-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"ADVL18P1 Dose Level - 1","valueDescription":"Lower Dose","ValueMeaning":{"publicId":"3295864","version":"1","preferredName":"Lower Dose","longName":"3295864","preferredDefinition":"To become lower, grow less, or diminish, as in amount, intensity, degree, or value.: The amount of medicine taken, or radiation given, at one time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lower","conceptCode":"C86568","definition":"To become lower, grow less, or diminish, as in amount, intensity, degree, or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFB4645C-6D58-2D30-E040-BB89AD43403A","latestVersionIndicator":"Yes","beginDate":"2011-10-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"997505B0-E3AD-6A24-E053-F662850A7802","beginDate":"2019-12-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-12-11","modifiedBy":"ONEDATA","dateModified":"2019-12-11","deletedIndicator":"No"},{"value":"AHEP1531 GroupF:ArmPGEMOX","valueDescription":"AHEP1531 GroupF:ArmPGEMOX","ValueMeaning":{"publicId":"7136818","version":"1","preferredName":"AHEP1531 GroupF:ArmPGEMOX","longName":"7136818","preferredDefinition":"AHEP1531 Group F:Arm PLADO/GEMOX","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C093C41-FC81-7D3F-E053-F662850A063C","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C093C41-FC9A-7D3F-E053-F662850A063C","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","deletedIndicator":"No"},{"value":"AHEP1531 GroupF: ArmPLADO","valueDescription":"AHEP1531 GroupF: ArmPLADO","ValueMeaning":{"publicId":"7136819","version":"1","preferredName":"AHEP1531 GroupF: ArmPLADO","longName":"7136819","preferredDefinition":"AHEP1531 Group F: Arm PLADO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C093C41-FCA4-7D3F-E053-F662850A063C","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C093C41-FCBD-7D3F-E053-F662850A063C","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","deletedIndicator":"No"},{"value":"AHEP1531 GroupC: ArmC5VD","valueDescription":"AHEP1531 GroupC: ArmC5VD","ValueMeaning":{"publicId":"7136820","version":"1","preferredName":"AHEP1531 GroupC: ArmC5VD","longName":"7136820","preferredDefinition":"AHEP1531 Group C: Arm C5VD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C093C41-FCC7-7D3F-E053-F662850A063C","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C093C41-FCE0-7D3F-E053-F662850A063C","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","deletedIndicator":"No"},{"value":"AHEP1531 GroupC: ArmCDDP","valueDescription":"AHEP1531 GroupC: ArmCDDP","ValueMeaning":{"publicId":"7136821","version":"1","preferredName":"AHEP1531 GroupC: ArmCDDP","longName":"7136821","preferredDefinition":"AHEP1531 Group C: Arm CDDP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C093C41-FCEA-7D3F-E053-F662850A063C","latestVersionIndicator":"Yes","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C093C41-FD03-7D3F-E053-F662850A063C","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","deletedIndicator":"No"},{"value":"Therapeutic Procedure","valueDescription":"Therapeutic Procedure","ValueMeaning":{"publicId":"4726231","version":"1","preferredName":"Therapeutic Procedure","longName":"4726231","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1013AB9C-32D4-698C-E050-BB89AD43129F","latestVersionIndicator":"Yes","beginDate":"2015-02-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-02-27","modifiedBy":"GDEEN","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9C093C41-FD17-7D3F-E053-F662850A063C","beginDate":"2020-01-13","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-01-13","modifiedBy":"ONEDATA","dateModified":"2020-01-13","deletedIndicator":"No"},{"value":"Arm B","valueDescription":"Arm B","ValueMeaning":{"publicId":"5644353","version":"1","preferredName":"Arm B","longName":"5644353","preferredDefinition":"Arm B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C05-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt VM Named added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A29AB35-1E06-08F4-E053-F662850AA368","beginDate":"2019-12-20","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-20","modifiedBy":"ONEDATA","dateModified":"2019-12-20","deletedIndicator":"No"},{"value":"Arm A","valueDescription":"Arm A","ValueMeaning":{"publicId":"5644354","version":"1","preferredName":"Arm A","longName":"5644354","preferredDefinition":"Arm A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476016AB-8C27-06A9-E053-F662850A1272","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-01-31","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.1.17 Alt SN added per ticket request CADSR0001913. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A29AB35-1E1A-08F4-E053-F662850AA368","beginDate":"2019-12-20","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-20","modifiedBy":"ONEDATA","dateModified":"2019-12-20","deletedIndicator":"No"},{"value":"Arm BD DL-1","valueDescription":"Arm BD: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","ValueMeaning":{"publicId":"7236081","version":"1","preferredName":"Arm BD: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","longName":"7236081","preferredDefinition":"Arm BD: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-978A-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-34FD-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm BD DL0","valueDescription":"Arm BD: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","ValueMeaning":{"publicId":"7236082","version":"1","preferredName":"Arm BD: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","longName":"7236082","preferredDefinition":"Arm BD: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-97AD-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-3512-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm BD DL1","valueDescription":"Arm BD: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","ValueMeaning":{"publicId":"7236083","version":"1","preferredName":"Arm BD: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","longName":"7236083","preferredDefinition":"Arm BD: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-97D0-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-3527-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm AD DL-1","valueDescription":"Arm AD: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","ValueMeaning":{"publicId":"7236084","version":"1","preferredName":"Arm AD: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","longName":"7236084","preferredDefinition":"Arm AD: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-97F3-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-353C-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm AD DL0","valueDescription":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 0 (1.5mg/kg/daily)","ValueMeaning":{"publicId":"7236085","version":"1","preferredName":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 0 (1.5mg/kg/daily)","longName":"7236085","preferredDefinition":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 0 (1.5mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-9816-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-3551-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm AD DL1","valueDescription":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","ValueMeaning":{"publicId":"7236086","version":"1","preferredName":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","longName":"7236086","preferredDefinition":"Arm AD: Standard Chemotherapy (DA +GO + Gilt) - DL 1 (2mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-9839-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-3566-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm BC DL-1","valueDescription":"Arm BC: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","ValueMeaning":{"publicId":"7236087","version":"1","preferredName":"Arm BC: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","longName":"7236087","preferredDefinition":"Arm BC: CPX-351 + Gilt - DL -1 (1mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-985C-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-357B-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm BC DL0","valueDescription":"Arm BC: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","ValueMeaning":{"publicId":"7236088","version":"1","preferredName":"Arm BC: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","longName":"7236088","preferredDefinition":"Arm BC: CPX-351 + GO + Gilt - DL 0 (1.5mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-987F-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-3590-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm BC DL1","valueDescription":"Arm BC: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","ValueMeaning":{"publicId":"7236089","version":"1","preferredName":"Arm BC: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","longName":"7236089","preferredDefinition":"Arm BC: CPX-351 + GO + Gilt - DL 1 (2mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-98A2-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-35A5-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm AC DL-1","valueDescription":"Arm AC: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","ValueMeaning":{"publicId":"7236090","version":"1","preferredName":"Arm AC: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","longName":"7236090","preferredDefinition":"Arm AC: Standard Chemotherapy (DA + Gilt) - DL -1 (1mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-98C5-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-35BA-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"Arm AC DL0","valueDescription":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) -DL 0 (1.5mg/kg/daily)","ValueMeaning":{"publicId":"7236091","version":"1","preferredName":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) -DL 0 (1.5mg/kg/daily)","longName":"7236091","preferredDefinition":"Arm AC: Standard Chemotherapy (DA +GO + Gilt) -DL 0 (1.5mg/kg/daily)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24FB8D8-98E8-4AFA-E053-F662850A4E5B","latestVersionIndicator":"Yes","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"SOKKERL","dateModified":"2020-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2532F18-35CF-7EA7-E053-F662850A0E95","beginDate":"2020-04-02","endDate":null,"createdBy":"LEEW","dateCreated":"2020-04-02","modifiedBy":"ONEDATA","dateModified":"2020-04-02","deletedIndicator":"No"},{"value":"AALL1732 Treatment 120","valueDescription":"120: HR-B-ALL Adherence - iIP","ValueMeaning":{"publicId":"7496434","version":"1","preferredName":"120: HR-B-ALL Adherence - iIP","longName":"7496434","preferredDefinition":"120: HR-B-ALL Adherence - iIP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B374B3C0-5B57-2CCE-E053-4EBD850AF7C7","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B374B3C0-5B70-2CCE-E053-4EBD850AF7C7","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"AALL1732 Treatment 130","valueDescription":"130: HR-B-ALL Adherence - U-iIP","ValueMeaning":{"publicId":"7496438","version":"1","preferredName":"130: HR-B-ALL Adherence - U-iIP","longName":"7496438","preferredDefinition":"130: HR-B-ALL Adherence - U-iIP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B374A2A1-9C56-163E-E053-4EBD850A3177","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B374A2A1-9C6F-163E-E053-4EBD850A3177","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","valueDescription":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","ValueMeaning":{"publicId":"7411324","version":"1","preferredName":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","longName":"7411324","preferredDefinition":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE46DBA3-FE51-0200-E053-4EBD850AB6F1","latestVersionIndicator":"Yes","beginDate":"2020-09-01","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE46DBA3-FE6A-0200-E053-4EBD850AB6F1","beginDate":"2020-09-01","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","deletedIndicator":"No"},{"value":"AALL1821 Treatment 60","valueDescription":"60: Down Syndrome Pre-immunotherapy Treatment","ValueMeaning":{"publicId":"7434200","version":"1","preferredName":"60: Down Syndrome Pre-immunotherapy Treatment","longName":"7434200","preferredDefinition":"60: Down Syndrome Pre-immunotherapy Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0145510-CBB2-3F32-E053-4EBD850A4473","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0145510-CBCB-3F32-E053-4EBD850A4473","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Regimen ICE Cyclo TOPO","valueDescription":"Regimen ICE/Cyclo/TOPO","ValueMeaning":{"publicId":"7309075","version":"1","preferredName":"Regimen ICE/Cyclo/TOPO","longName":"7309075","preferredDefinition":"Regimen ICE/Cyclo/TOPO","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B7DD4C-2930-3473-E053-4EBD850AB4CC","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"GALITG","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6B7DD4C-2949-3473-E053-4EBD850AB4CC","beginDate":"2020-05-28","endDate":null,"createdBy":"GALITG","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"},{"value":"Regimen UH-3","valueDescription":"Regimen UH-3","ValueMeaning":{"publicId":"7309076","version":"1","preferredName":"Regimen UH-3","longName":"7309076","preferredDefinition":"Regimen UH-3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B7DD4C-2953-3473-E053-4EBD850AB4CC","latestVersionIndicator":"Yes","beginDate":"2020-05-28","endDate":null,"createdBy":"GALITG","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6B7DD4C-296C-3473-E053-4EBD850AB4CC","beginDate":"2020-05-28","endDate":null,"createdBy":"GALITG","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"},{"value":"AALL1821 Treatment 40","valueDescription":"40: Group 1 Pre-immunotherapy Treatment","ValueMeaning":{"publicId":"7434201","version":"1","preferredName":"40: Group 1 Pre-immunotherapy Treatment","longName":"7434201","preferredDefinition":"40: Group 1 Pre-immunotherapy Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0145510-CBD5-3F32-E053-4EBD850A4473","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0145510-CBEE-3F32-E053-4EBD850A4473","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"ANHL1931 Arm F: R CHOP plus radiotherapy plus nivolumab","valueDescription":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7524419","version":"1","preferredName":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","longName":"7524419","preferredDefinition":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD12-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FD2B-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"ANHL1931 Arm E R CHOP plus radiotherapy","valueDescription":"Arm E: R-CHOP + radiotherapy","ValueMeaning":{"publicId":"7524420","version":"1","preferredName":"Arm E: R-CHOP + radiotherapy","longName":"7524420","preferredDefinition":"Arm E: R-CHOP + radiotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD35-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FD4E-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"ANHL1931 Arm D R CHOP plus nivolumab","valueDescription":"Arm D: R-CHOP +  nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7524421","version":"1","preferredName":"Arm D: R-CHOP +  nivolumab per IV infusion for 30 minutes","longName":"7524421","preferredDefinition":"Arm D: R-CHOP +  nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD58-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FD71-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"ANHL1931 Arm C R CHOP","valueDescription":"Arm C: R-CHOP","ValueMeaning":{"publicId":"7524422","version":"1","preferredName":"Arm C: R-CHOP","longName":"7524422","preferredDefinition":"Arm C: R-CHOP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD7B-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FD94-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"ANHL1931 Arm B DA-EPOCH-R plus nivolumab","valueDescription":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7524423","version":"1","preferredName":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","longName":"7524423","preferredDefinition":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD9E-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FDB7-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"ANHL1931 Arm A DA-EPOCH-R","valueDescription":"Arm A: DA-EPOCH-R","ValueMeaning":{"publicId":"7524424","version":"1","preferredName":"Arm A: DA-EPOCH-R","longName":"7524424","preferredDefinition":"Arm A: DA-EPOCH-R","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FDC1-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B593EFD3-FDDA-0CE5-E053-4EBD850A572A","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"},{"value":"AALL1821 Treatment 120","valueDescription":"120: Arm F- Nivolumab and Blinatumomab Combination Therapy","ValueMeaning":{"publicId":"7434337","version":"1","preferredName":"120: Arm F- Nivolumab and Blinatumomab Combination Therapy","longName":"7434337","preferredDefinition":"120: Arm F- Nivolumab and Blinatumomab Combination Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-773E-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-7757-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 110","valueDescription":"110: Arm E- Blinatumomab Monotherapy","ValueMeaning":{"publicId":"7434338","version":"1","preferredName":"110: Arm E- Blinatumomab Monotherapy","longName":"7434338","preferredDefinition":"110: Arm E- Blinatumomab Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-7761-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-777A-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 100","valueDescription":"100: Arm D- Nivolumab and Blinatumomab Combination Therapy","ValueMeaning":{"publicId":"7434339","version":"1","preferredName":"100: Arm D- Nivolumab and Blinatumomab Combination Therapy","longName":"7434339","preferredDefinition":"100: Arm D- Nivolumab and Blinatumomab Combination Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-7784-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-779D-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 90","valueDescription":"90: Arm C- Blinatumomab Monotherapy","ValueMeaning":{"publicId":"7434340","version":"1","preferredName":"90: Arm C- Blinatumomab Monotherapy","longName":"7434340","preferredDefinition":"90: Arm C- Blinatumomab Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-77A7-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-77C0-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 130","valueDescription":"130: Arm G- Down Syndrome Nivolumab and Blinatumomab Combination Therapy","ValueMeaning":{"publicId":"7434341","version":"1","preferredName":"130: Arm G- Down Syndrome Nivolumab and Blinatumomab Combination Therapy","longName":"7434341","preferredDefinition":"130: Arm G- Down Syndrome Nivolumab and Blinatumomab Combination Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-77CA-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-77E3-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 80","valueDescription":"80: Arm B- Nivolumab and Blinatumomab Combination Therapy","ValueMeaning":{"publicId":"7434342","version":"1","preferredName":"80: Arm B- Nivolumab and Blinatumomab Combination Therapy","longName":"7434342","preferredDefinition":"80: Arm B- Nivolumab and Blinatumomab Combination Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-77ED-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-7806-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 70","valueDescription":"70: Arm A- Blinatumomab Monotherapy","ValueMeaning":{"publicId":"7434343","version":"1","preferredName":"70: Arm A- Blinatumomab Monotherapy","longName":"7434343","preferredDefinition":"70: Arm A- Blinatumomab Monotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B014CE6A-7810-28D3-E053-4EBD850A9B1C","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B014CE6A-7829-28D3-E053-4EBD850A9B1C","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"AALL1821 Treatment 30","valueDescription":"Down Syndrome Therapy","ValueMeaning":{"publicId":"7461318","version":"1","preferredName":"Down Syndrome Therapy","longName":"7461318","preferredDefinition":"Down Syndrome Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B11D4A4F-3C24-12FC-E053-4EBD850ADB98","latestVersionIndicator":"Yes","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B11D4A4F-3C3D-12FC-E053-4EBD850ADB98","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","deletedIndicator":"No"},{"value":"AALL1821 Treatment 20","valueDescription":"Group 2/3 Therapy","ValueMeaning":{"publicId":"7461319","version":"1","preferredName":"Group 2/3 Therapy","longName":"7461319","preferredDefinition":"Group 2/3 Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B11D4A4F-3C47-12FC-E053-4EBD850ADB98","latestVersionIndicator":"Yes","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B11D4A4F-3C60-12FC-E053-4EBD850ADB98","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","deletedIndicator":"No"},{"value":"AALL1821 Treatment 10","valueDescription":"Group 1 Therapy","ValueMeaning":{"publicId":"7461320","version":"1","preferredName":"Group 1 Therapy","longName":"7461320","preferredDefinition":"Group 1 Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B11D4A4F-3C6A-12FC-E053-4EBD850ADB98","latestVersionIndicator":"Yes","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B11D4A4F-3C83-12FC-E053-4EBD850ADB98","beginDate":"2020-10-07","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-10-07","modifiedBy":"ONEDATA","dateModified":"2020-10-07","deletedIndicator":"No"},{"value":"AALL1732 Treatment 110","valueDescription":"110: HR-B-ALL Adherence - EDU","ValueMeaning":{"publicId":"7496363","version":"1","preferredName":"110: HR-B-ALL Adherence - EDU","longName":"7496363","preferredDefinition":"110: HR-B-ALL Adherence - EDU","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3737DD5-FD9E-28F0-E053-4EBD850A010A","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3737DD5-FDB7-28F0-E053-4EBD850A010A","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"Screening","valueDescription":"Screening","ValueMeaning":{"publicId":"2570677","version":"1","preferredName":"Screening","longName":"2570677","preferredDefinition":"A systematic examination or assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Screening","conceptCode":"C48261","definition":"A systematic examination or assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E122-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"LISU","dateModified":"2022-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B21F897B-60BB-2AEC-E053-4EBD850A1689","beginDate":"2020-10-20","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-20","modifiedBy":"ONEDATA","dateModified":"2020-10-20","deletedIndicator":"No"},{"value":"AALL1732 Treatment 100","valueDescription":"100: HR-B-ALL Adherence - pIP","ValueMeaning":{"publicId":"7496359","version":"1","preferredName":"100: HR-B-ALL Adherence - pIP","longName":"7496359","preferredDefinition":"100: HR-B-ALL Adherence - pIP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3732A67-178E-53A5-E053-4EBD850A8FBA","latestVersionIndicator":"Yes","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3732A67-17A7-53A5-E053-4EBD850A8FBA","beginDate":"2020-11-06","endDate":null,"createdBy":"WOODC","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"Selumetinib","valueDescription":"Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID","ValueMeaning":{"publicId":"7452207","version":"1","preferredName":"Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID","longName":"7452207","preferredDefinition":"Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0A372EB-C515-3B8C-E053-4EBD850AA300","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0A372EB-C52E-3B8C-E053-4EBD850AA300","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","deletedIndicator":"No"},{"value":"Dose Level 2","valueDescription":"Dose Level 2: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 5 mg/m2","ValueMeaning":{"publicId":"7452208","version":"1","preferredName":"Dose Level 2: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 5 mg/m2","longName":"7452208","preferredDefinition":"Dose Level 2: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 5 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0A372EB-C538-3B8C-E053-4EBD850AA300","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"MAESKEB","dateModified":"2021-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0A372EB-C551-3B8C-E053-4EBD850AA300","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","deletedIndicator":"No"},{"value":"Dose Level 1","valueDescription":"Dose Level 1: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 4 mg/m2","ValueMeaning":{"publicId":"7452209","version":"1","preferredName":"Dose Level 1: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 4 mg/m2","longName":"7452209","preferredDefinition":"Dose Level 1: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 4 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0A372EB-C55B-3B8C-E053-4EBD850AA300","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"MAESKEB","dateModified":"2021-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0A372EB-C574-3B8C-E053-4EBD850AA300","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","deletedIndicator":"No"},{"value":"Dose Level 0","valueDescription":"Dose Level 0: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 3 mg/m2","ValueMeaning":{"publicId":"7452210","version":"1","preferredName":"Dose Level 0: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 3 mg/m2","longName":"7452210","preferredDefinition":"Dose Level 0: Selumetinib 25 mg/m2/dose, max 50 mg/dose, BID + Vinblastine 3 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0A372EB-C57E-3B8C-E053-4EBD850AA300","latestVersionIndicator":"Yes","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0A372EB-C597-3B8C-E053-4EBD850AA300","beginDate":"2020-10-01","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2020-10-01","modifiedBy":"ONEDATA","dateModified":"2020-10-01","deletedIndicator":"No"},{"value":"Memantine","valueDescription":"Memantine","ValueMeaning":{"publicId":"4599972","version":"1","preferredName":"Memantine","longName":"4599972","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Memantine","conceptCode":"C73269","definition":"A low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine type 3 (5HT3) receptor and nicotinic receptor antagonist.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08391E69-9B09-0735-E050-BB89AD4304D6","latestVersionIndicator":"Yes","beginDate":"2014-11-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B042242D-CB2B-46C3-E053-4EBD850AF81C","beginDate":"2020-09-26","endDate":null,"createdBy":"WANGC","dateCreated":"2020-09-26","modifiedBy":"ONEDATA","dateModified":"2020-09-26","deletedIndicator":"No"},{"value":"ANBL19P1 Treatment","valueDescription":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","ValueMeaning":{"publicId":"7411324","version":"1","preferredName":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","longName":"7411324","preferredDefinition":"ANBL19P1 Treatment of Dinutuximab in Combination with Irinotecan, Temozolomide, Sargramostim (GM-CSF), and Isotretinoin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE46DBA3-FE51-0200-E053-4EBD850AB6F1","latestVersionIndicator":"Yes","beginDate":"2020-09-01","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2EA6471-9C15-576B-E053-4EBD850A4D68","beginDate":"2020-10-30","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2020-10-30","modifiedBy":"ONEDATA","dateModified":"2020-10-30","deletedIndicator":"No"},{"value":"AALL1821 Treatment 50","valueDescription":"50: VXLD Reinduction","ValueMeaning":{"publicId":"7502552","version":"1","preferredName":"50: VXLD Reinduction","longName":"7502552","preferredDefinition":"50: VXLD Reinduction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3EFB01C-3018-1B6B-E053-4EBD850AE994","latestVersionIndicator":"Yes","beginDate":"2020-11-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-11-12","modifiedBy":"ONEDATA","dateModified":"2020-11-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3EFB01C-3031-1B6B-E053-4EBD850AE994","beginDate":"2020-11-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-11-12","modifiedBy":"ONEDATA","dateModified":"2020-11-12","deletedIndicator":"No"},{"value":"Craniospinal Irradiation","valueDescription":"Craniospinal Irradiation","ValueMeaning":{"publicId":"5028294","version":"1","preferredName":"Craniospinal Irradiation","longName":"5028294","preferredDefinition":"The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniospinal Irradiation","conceptCode":"C116437","definition":"The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2189EF50-FFA7-CB37-E050-BB89AD437EA1","latestVersionIndicator":"Yes","beginDate":"2015-10-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C23EBE3F-25E5-2F33-E053-4EBD850A52F8","beginDate":"2021-05-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-13","modifiedBy":"ONEDATA","dateModified":"2021-05-13","deletedIndicator":"No"},{"value":"Consolidation Therapy","valueDescription":"Consolidation Therapy","ValueMeaning":{"publicId":"3828965","version":"1","preferredName":"Consolidation Therapy","longName":"3828965","preferredDefinition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Consolidation Therapy","conceptCode":"C15679","definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2C14-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-29","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C23EBE3F-25FB-2F33-E053-4EBD850A52F8","beginDate":"2021-05-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-13","modifiedBy":"ONEDATA","dateModified":"2021-05-13","deletedIndicator":"No"},{"value":"Radiation Therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C23EBE3F-2607-2F33-E053-4EBD850A52F8","beginDate":"2021-05-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-13","modifiedBy":"ONEDATA","dateModified":"2021-05-13","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgical Procedure","ValueMeaning":{"publicId":"3440172","version":"1","preferredName":"Surgical Procedure","longName":"3440172","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE12571D-0867-9ACA-E040-BB89AD4324C1","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-19","modifiedBy":"KUMMEROA","dateModified":"2024-02-22","changeDescription":"Added OBIB alternate name and identifier DW 03-21-2019","administrativeNotes":"2023.1.20 Alt VM added per ticket request CADSR0001943. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C23EBE3F-2612-2F33-E053-4EBD850A52F8","beginDate":"2021-05-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-13","modifiedBy":"ONEDATA","dateModified":"2021-05-13","deletedIndicator":"No"},{"value":"ANHL1931 Arm F","valueDescription":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7524419","version":"1","preferredName":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","longName":"7524419","preferredDefinition":"Arm F: R-CHOP + radiotherapy + nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD12-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8CF9-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"ANHL1931 Arm E","valueDescription":"Arm E: R-CHOP + radiotherapy","ValueMeaning":{"publicId":"7524420","version":"1","preferredName":"Arm E: R-CHOP + radiotherapy","longName":"7524420","preferredDefinition":"Arm E: R-CHOP + radiotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD35-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8D0D-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"ANHL1931 Arm D","valueDescription":"Arm D: R-CHOP + nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7607851","version":"1","preferredName":"Arm D: R-CHOP + nivolumab per IV infusion for 30 minutes","longName":"7607851","preferredDefinition":"Arm D: R-CHOP + nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE278744-8D17-4B10-E053-4EBD850ADACF","latestVersionIndicator":"Yes","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8D30-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"ANHL1931 Arm C","valueDescription":"Arm C: R-CHOP","ValueMeaning":{"publicId":"7524422","version":"1","preferredName":"Arm C: R-CHOP","longName":"7524422","preferredDefinition":"Arm C: R-CHOP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD7B-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8D44-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"ANHL1931 Arm B","valueDescription":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","ValueMeaning":{"publicId":"7524423","version":"1","preferredName":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","longName":"7524423","preferredDefinition":"Arm B: DA-EPOCH-R + nivolumab per IV infusion for 30 minutes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FD9E-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8D58-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"ANHL1931 Arm A","valueDescription":"Arm A: DA-EPOCH-R","ValueMeaning":{"publicId":"7524424","version":"1","preferredName":"Arm A: DA-EPOCH-R","longName":"7524424","preferredDefinition":"Arm A: DA-EPOCH-R","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B593EFD3-FDC1-0CE5-E053-4EBD850A572A","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"GALITG","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE278744-8D6C-4B10-E053-4EBD850ADACF","beginDate":"2021-03-22","endDate":null,"createdBy":"GALITG","dateCreated":"2021-03-22","modifiedBy":"ONEDATA","dateModified":"2021-03-22","deletedIndicator":"No"},{"value":"HDCSCR","valueDescription":"High-dose chemotherapy with stem cell rescue","ValueMeaning":{"publicId":"7665064","version":"1","preferredName":"High-dose chemotherapy with stem cell rescue","longName":"7665064","preferredDefinition":"High-dose chemotherapy with stem cell rescue","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C28AF346-D0D3-119A-E053-4EBD850AA1DE","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-17","modifiedBy":"ONEDATA","dateModified":"2021-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C28AF346-D0EC-119A-E053-4EBD850AA1DE","beginDate":"2021-05-17","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-17","modifiedBy":"ONEDATA","dateModified":"2021-05-17","deletedIndicator":"No"},{"value":"WVSCI","valueDescription":"Whole ventricular + spinal canal irradiation","ValueMeaning":{"publicId":"7665065","version":"1","preferredName":"Whole ventricular + spinal canal irradiation","longName":"7665065","preferredDefinition":"Whole ventricular + spinal canal irradiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C28AF346-D0F6-119A-E053-4EBD850AA1DE","latestVersionIndicator":"Yes","beginDate":"2021-05-17","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-17","modifiedBy":"ONEDATA","dateModified":"2021-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C28AF346-D10F-119A-E053-4EBD850AA1DE","beginDate":"2021-05-17","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-05-17","modifiedBy":"ONEDATA","dateModified":"2021-05-17","deletedIndicator":"No"},{"value":"InO DL-2 + mBFM Chemo","valueDescription":"InO DL-2 + mBFM Chemo","ValueMeaning":{"publicId":"7588900","version":"1","preferredName":"InO DL-2 + mBFM Chemo","longName":"7588900","preferredDefinition":"Inotuzumab Ozogamicin Dose Level -2 (1.1/0.9 mg/m^2 dose/cycle) + Augmented mBFM Consolidation Chemotherapy omitting vincristine and PEGasparase","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC948E49-4DE2-10F3-E053-4EBD850A4FFF","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"KUMMEROA","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC948E49-4DFB-10F3-E053-4EBD850A4FFF","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","deletedIndicator":"No"},{"value":"InO DL-1 + mBFM Chemo","valueDescription":"InO DL-1 + mBFM Chemo","ValueMeaning":{"publicId":"7588901","version":"1","preferredName":"InO DL-1 + mBFM Chemo","longName":"7588901","preferredDefinition":"Inotuzumab Ozogamicin Dose Level -1 (1.1/0.9 mg/m^2 dose/cycle) + Augmented mBFM Consolidation Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC948E49-4E05-10F3-E053-4EBD850A4FFF","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC948E49-4E1E-10F3-E053-4EBD850A4FFF","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","deletedIndicator":"No"},{"value":"InO DL1 + mBFM Chemo","valueDescription":"InO DL1 + mBFM Chemo","ValueMeaning":{"publicId":"7588902","version":"1","preferredName":"InO DL1 + mBFM Chemo","longName":"7588902","preferredDefinition":"Inotuzumab Ozogamicin Dose Level 1 (1.4/1.2 mg/m^2 dose/cycle) + Augmented mBFM Consolidation Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC948E49-4E28-10F3-E053-4EBD850A4FFF","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC948E49-4E41-10F3-E053-4EBD850A4FFF","beginDate":"2021-03-02","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","deletedIndicator":"No"},{"value":"Regimen B : VINO-AC + VINO-CPO","valueDescription":"Regimen B : VINO-AC + VINO-CPO","ValueMeaning":{"publicId":"7741529","version":"1","preferredName":"Regimen B : VINO-AC + VINO-CPO","longName":"7741529","preferredDefinition":"ARST2031 Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C72E6DCA-8464-2DCF-E053-4EBD850AEE49","latestVersionIndicator":"Yes","beginDate":"2021-07-15","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C72E6DCA-847D-2DCF-E053-4EBD850AEE49","beginDate":"2021-07-15","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","deletedIndicator":"No"},{"value":"Regimen A: VAC + VINO-CPO","valueDescription":"Regimen A: VAC + VINO-CPO","ValueMeaning":{"publicId":"7741530","version":"1","preferredName":"Regimen A: VAC + VINO-CPO","longName":"7741530","preferredDefinition":"ARST2031 Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C72E6DCA-8487-2DCF-E053-4EBD850AEE49","latestVersionIndicator":"Yes","beginDate":"2021-07-15","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C72E6DCA-84A0-2DCF-E053-4EBD850AEE49","beginDate":"2021-07-15","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","deletedIndicator":"No"},{"value":"Regimen B","valueDescription":"Regimen B: VINO-AC + VINO-Cpo","ValueMeaning":{"publicId":"7767220","version":"1","preferredName":"Regimen B: VINO-AC + VINO-Cpo","longName":"7767220","preferredDefinition":"Regimen B: VINO-AC + VINO-Cpo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9C39940-7529-39AE-E053-4EBD850A6FFB","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-08-17","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.2 Alt def added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C9C39940-7542-39AE-E053-4EBD850A6FFB","beginDate":"2021-08-17","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","deletedIndicator":"No"},{"value":"Regimen A","valueDescription":"Regimen A: VAC + VINO-Cpo","ValueMeaning":{"publicId":"7767221","version":"1","preferredName":"Regimen A: VAC + VINO-Cpo","longName":"7767221","preferredDefinition":"Regimen A: VAC + VINO-Cpo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9C39940-754C-39AE-E053-4EBD850A6FFB","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-08-17","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.2 Alt def added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C9C39940-7565-39AE-E053-4EBD850A6FFB","beginDate":"2021-08-17","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","deletedIndicator":"No"},{"value":"Reduced RT/Chemo/STS","valueDescription":"Reduced RT/Chemo/STS","ValueMeaning":{"publicId":"7975086","version":"1","preferredName":"Reduced RT/Chemo/STS","longName":"7975086","preferredDefinition":"Reduced RT/Chemo/STS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D06C37-7A17-3B24-E053-4EBD850A35DD","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-10","modifiedBy":"KUMMEROA","dateModified":"2022-10-28","changeDescription":null,"administrativeNotes":"2022.10.28 Added Alt Def and Alt Name for ticket request CADSR0001632. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2D06C37-7A30-3B24-E053-4EBD850A35DD","beginDate":"2021-12-10","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","deletedIndicator":"No"},{"value":"Standard RT/Chemo/STS","valueDescription":"Standard RT/Chemo/STS","ValueMeaning":{"publicId":"7975087","version":"1","preferredName":"Standard RT/Chemo/STS","longName":"7975087","preferredDefinition":"Standard RT/Chemo/STS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2D06C37-7A3A-3B24-E053-4EBD850A35DD","latestVersionIndicator":"Yes","beginDate":"2021-12-10","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-10","modifiedBy":"KUMMEROA","dateModified":"2022-10-28","changeDescription":null,"administrativeNotes":"2022.10.28 Added Alt Name/Def for ticket request CADSR0001632. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2D06C37-7A53-3B24-E053-4EBD850A35DD","beginDate":"2021-12-10","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-10","modifiedBy":"ONEDATA","dateModified":"2021-12-10","deletedIndicator":"No"},{"value":"Thoracotomy","valueDescription":"Thoracotomy","ValueMeaning":{"publicId":"3124186","version":"1","preferredName":"Thoracotomy","longName":"3124186","preferredDefinition":"Surgical opening of the mediastinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Macrophage Colony-Stimulating Factor/Monoclonal Antibody R24","conceptCode":"C15537","definition":"Surgical opening of the mediastinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BFEF234-3401-944B-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2010-07-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D34845C7-DAE5-4164-E053-4EBD850AE3F6","beginDate":"2021-12-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-16","modifiedBy":"ONEDATA","dateModified":"2021-12-16","deletedIndicator":"No"},{"value":"Thoracoscopy","valueDescription":"Thoracoscopy","ValueMeaning":{"publicId":"2833132","version":"1","preferredName":"Thoracoscopy","longName":"2833132","preferredDefinition":"The use of a thin, lighted tube (called an endoscope) to examine the inside of the chest.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thoracoscopy","conceptCode":"C17196","definition":"Endoscopic examination of the thoracic cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"621D07D9-060C-271C-E040-BB89AD43153D","latestVersionIndicator":"Yes","beginDate":"2009-02-04","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-04","modifiedBy":"ONEDATA","dateModified":"2009-02-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D34845C7-DAEF-4164-E053-4EBD850AE3F6","beginDate":"2021-12-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2021-12-16","modifiedBy":"ONEDATA","dateModified":"2021-12-16","deletedIndicator":"No"},{"value":"ANHL2121 Treatment 20","valueDescription":"AGENT","ValueMeaning":{"publicId":"2573428","version":"1","preferredName":"AGENT","longName":"2573428","preferredDefinition":"AGENT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-14","endDate":null,"createdBy":"PWEST","dateCreated":"2005-03-14","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6B446B7-C3FB-2001-E053-4EBD850AF965","beginDate":"2022-01-29","endDate":null,"createdBy":"GALITG","dateCreated":"2022-01-29","modifiedBy":"ONEDATA","dateModified":"2022-01-29","deletedIndicator":"No"},{"value":"ANHL2121 Treatment 10","valueDescription":"AGENT","ValueMeaning":{"publicId":"2573428","version":"1","preferredName":"AGENT","longName":"2573428","preferredDefinition":"AGENT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-14","endDate":null,"createdBy":"PWEST","dateCreated":"2005-03-14","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6B446B7-C3E6-2001-E053-4EBD850AF965","beginDate":"2022-01-29","endDate":null,"createdBy":"GALITG","dateCreated":"2022-01-29","modifiedBy":"ONEDATA","dateModified":"2022-01-29","deletedIndicator":"No"},{"value":"DL-2","valueDescription":"DL-2: IMGN632 (0.05 mg/kg on Days 1 only)","ValueMeaning":{"publicId":"8029192","version":"1","preferredName":"DL-2","longName":"8029192","preferredDefinition":"DL-2: IMGN632 (0.05 mg/kg on Days 1 only)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D773D1B7-6F43-743E-E053-4EBD850AAF5C","latestVersionIndicator":"Yes","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D773D1B7-6F5C-743E-E053-4EBD850AAF5C","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","deletedIndicator":"No"},{"value":"DL-1","valueDescription":"DL-1: IMGN632 (0.05 mg/kg on Days 1 and 0.02 mg/kg on Day 22)","ValueMeaning":{"publicId":"8029193","version":"1","preferredName":"DL-1","longName":"8029193","preferredDefinition":"DL-1: IMGN632 (0.05 mg/kg on Days 1 and 0.02 mg/kg on Day 22)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D773D1B7-6F66-743E-E053-4EBD850AAF5C","latestVersionIndicator":"Yes","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D773D1B7-6F7F-743E-E053-4EBD850AAF5C","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","deletedIndicator":"No"},{"value":"DL2","valueDescription":"DL2: IMGN632 (0.1 mg/kg on Days 1 and 22)","ValueMeaning":{"publicId":"8029194","version":"1","preferredName":"DL2","longName":"8029194","preferredDefinition":"DL2: IMGN632 (0.1 mg/kg on Days 1 and 22)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D773D1B7-6F89-743E-E053-4EBD850AAF5C","latestVersionIndicator":"Yes","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D773D1B7-6FA2-743E-E053-4EBD850AAF5C","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","deletedIndicator":"No"},{"value":"DL1","valueDescription":"DL1: IMGN632 (0.05 mg/kg on Days 1 and 22)","ValueMeaning":{"publicId":"8029195","version":"1","preferredName":"DL1","longName":"8029195","preferredDefinition":"DL1: IMGN632 (0.05 mg/kg on Days 1 and 22)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D773D1B7-6FAC-743E-E053-4EBD850AAF5C","latestVersionIndicator":"Yes","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D773D1B7-6FC5-743E-E053-4EBD850AAF5C","beginDate":"2022-02-07","endDate":null,"createdBy":"LEEW","dateCreated":"2022-02-07","modifiedBy":"KUMMEROA","dateModified":"2022-06-28","deletedIndicator":"No"},{"value":"ANHL2121 Treatment","valueDescription":"DAY101 Dose -1: 280 mg/m2 (max 400 mg/dose)","ValueMeaning":{"publicId":"8172655","version":"1","preferredName":"DAY101 Dose -1: 280 mg/m2 (max 400 mg/dose)","longName":"8172655","preferredDefinition":"DAY101 Dose -1: 280 mg/m2 (max 400 mg/dose)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCF585AD-80DB-5DC2-E053-4EBD850AB62A","latestVersionIndicator":"Yes","beginDate":"2022-04-18","endDate":null,"createdBy":"GALITG","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCF585AD-80F4-5DC2-E053-4EBD850AB62A","beginDate":"2022-04-18","endDate":null,"createdBy":"GALITG","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","deletedIndicator":"No"},{"value":"Arm B: MUD BMT","valueDescription":"Arm B: MUD BMT","ValueMeaning":{"publicId":"8176855","version":"1","preferredName":"Arm B: MUD BMT","longName":"8176855","preferredDefinition":"Arm B: MUD BMT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD94C780-50E1-5624-E053-4EBD850A148E","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD94C780-50FA-5624-E053-4EBD850A148E","beginDate":"2022-04-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-26","modifiedBy":"ONEDATA","dateModified":"2022-04-26","deletedIndicator":"No"},{"value":"ACNS1821 Dose Level 3","valueDescription":"Dose Level 3: Selinexor 55 mg/m2 + RT + (Maintenance) Selinexor 55 mg/m2","ValueMeaning":{"publicId":"8040190","version":"1","preferredName":"Dose Level 3: Selinexor 55 mg/m2 + RT + (Maintenance) Selinexor 55 mg/m2","longName":"8040190","preferredDefinition":"Dose Level 3: Selinexor 55 mg/m2 + RT + (Maintenance) Selinexor 55 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D814B759-4215-37FF-E053-4EBD850AF3F1","latestVersionIndicator":"Yes","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D814B759-422E-37FF-E053-4EBD850AF3F1","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","deletedIndicator":"No"},{"value":"ACNS1821 Dose Level 2","valueDescription":"Dose Level 2: Selinexor 45 mg/m2 + RT + (Maintenance) Selinexor 45 mg/m2","ValueMeaning":{"publicId":"8040191","version":"1","preferredName":"Dose Level 2: Selinexor 45 mg/m2 + RT + (Maintenance) Selinexor 45 mg/m2","longName":"8040191","preferredDefinition":"Dose Level 2: Selinexor 45 mg/m2 + RT + (Maintenance) Selinexor 45 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D814B759-4238-37FF-E053-4EBD850AF3F1","latestVersionIndicator":"Yes","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D814B759-4251-37FF-E053-4EBD850AF3F1","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","deletedIndicator":"No"},{"value":"ACNS1821 Dose Level 1","valueDescription":"Dose Level 1: Selinexor 35 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","ValueMeaning":{"publicId":"8040192","version":"1","preferredName":"Dose Level 1: Selinexor 35 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","longName":"8040192","preferredDefinition":"Dose Level 1: Selinexor 35 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D814B759-425B-37FF-E053-4EBD850AF3F1","latestVersionIndicator":"Yes","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D814B759-4274-37FF-E053-4EBD850AF3F1","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","deletedIndicator":"No"},{"value":"ACNS1821 Dose Level -1","valueDescription":"Dose Level -1: Selinexor 25 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","ValueMeaning":{"publicId":"8040193","version":"1","preferredName":"Dose Level -1: Selinexor 25 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","longName":"8040193","preferredDefinition":"Dose Level -1: Selinexor 25 mg/m2 + RT + (Maintenance) Selinexor 35 mg/m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D814B759-427E-37FF-E053-4EBD850AF3F1","latestVersionIndicator":"Yes","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D814B759-4297-37FF-E053-4EBD850AF3F1","beginDate":"2022-02-15","endDate":null,"createdBy":"SHIEHI","dateCreated":"2022-02-15","modifiedBy":"ONEDATA","dateModified":"2022-02-15","deletedIndicator":"No"},{"value":"Regimen M","valueDescription":"Regimen M only","ValueMeaning":{"publicId":"8093829","version":"1","preferredName":"Regimen M only","longName":"8093829","preferredDefinition":"Regimen M only","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA78B22A-9915-11B3-E053-4EBD850AB749","latestVersionIndicator":"Yes","beginDate":"2022-03-18","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-18","modifiedBy":"ONEDATA","dateModified":"2022-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC7AE10E-7059-24F5-E053-4EBD850A63E3","beginDate":"2022-03-18","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-04-12","modifiedBy":"ONEDATA","dateModified":"2022-04-12","deletedIndicator":"No"},{"value":"Regimen VAC/VA","valueDescription":"Regimen VAC/VA","ValueMeaning":{"publicId":"8092631","version":"1","preferredName":"Regimen VAC/VA","longName":"8092631","preferredDefinition":"Regimen VAC/VA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA5A56F3-A86F-552D-E053-4EBD850A2DEE","latestVersionIndicator":"Yes","beginDate":"2022-03-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-16","modifiedBy":"ONEDATA","dateModified":"2022-03-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA5A56F3-A888-552D-E053-4EBD850A2DEE","beginDate":"2022-03-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-16","modifiedBy":"ONEDATA","dateModified":"2022-03-16","deletedIndicator":"No"},{"value":"Regimen VA","valueDescription":"Regimen VA","ValueMeaning":{"publicId":"8092632","version":"1","preferredName":"Regimen VA","longName":"8092632","preferredDefinition":"Regimen VA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA5A56F3-A892-552D-E053-4EBD850A2DEE","latestVersionIndicator":"Yes","beginDate":"2022-03-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-16","modifiedBy":"ONEDATA","dateModified":"2022-03-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA5A56F3-A8AB-552D-E053-4EBD850A2DEE","beginDate":"2022-03-16","endDate":null,"createdBy":"MACASAC","dateCreated":"2022-03-16","modifiedBy":"ONEDATA","dateModified":"2022-03-16","deletedIndicator":"No"},{"value":"Arm C: Haplo BMT","valueDescription":"Arm C: Haplo BMT","ValueMeaning":{"publicId":"8147045","version":"1","preferredName":"Arm C: Haplo BMT","longName":"8147045","preferredDefinition":"Arm C: Haplo BMT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC0255AD-D548-3503-E053-4EBD850A04C3","latestVersionIndicator":"Yes","beginDate":"2022-04-06","endDate":null,"createdBy":"BROWNTY","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC0255AD-D561-3503-E053-4EBD850A04C3","beginDate":"2022-04-06","endDate":null,"createdBy":"BROWNTY","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","deletedIndicator":"No"},{"value":"Arm A: Haplo BMT","valueDescription":"Arm A: Haplo BMT","ValueMeaning":{"publicId":"8147046","version":"1","preferredName":"Arm A: Haplo BMT","longName":"8147046","preferredDefinition":"Arm A: Haplo BMT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC0255AD-D56B-3503-E053-4EBD850A04C3","latestVersionIndicator":"Yes","beginDate":"2022-04-06","endDate":null,"createdBy":"BROWNTY","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC0255AD-D584-3503-E053-4EBD850A04C3","beginDate":"2022-04-06","endDate":null,"createdBy":"BROWNTY","dateCreated":"2022-04-06","modifiedBy":"ONEDATA","dateModified":"2022-04-06","deletedIndicator":"No"},{"value":"ASCT2031 Arm C","valueDescription":"Arm C: Haplo BMT (Non-Randomized)","ValueMeaning":{"publicId":"8075240","version":"1","preferredName":"Arm C: Haplo BMT (Non-Randomized)","longName":"8075240","preferredDefinition":"Arm C: Haplo BMT (Non-Randomized)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9CD87C9-2342-08D2-E053-4EBD850A1A74","latestVersionIndicator":"Yes","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9CD87C9-235B-08D2-E053-4EBD850A1A74","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","deletedIndicator":"No"},{"value":"ASCT2031 Arm B","valueDescription":"Arm B: MUD BMT","ValueMeaning":{"publicId":"8075241","version":"1","preferredName":"Arm B: MUD BMT","longName":"8075241","preferredDefinition":"Arm B: MUD BMT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9CD87C9-2365-08D2-E053-4EBD850A1A74","latestVersionIndicator":"Yes","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9CD87C9-237E-08D2-E053-4EBD850A1A74","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","deletedIndicator":"No"},{"value":"ASCT2031 Arm A","valueDescription":"Arm A: Haplo BMT (Randomized)","ValueMeaning":{"publicId":"8075242","version":"1","preferredName":"Arm A: Haplo BMT (Randomized)","longName":"8075242","preferredDefinition":"Arm A: Haplo BMT (Randomized)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9CD87C9-2388-08D2-E053-4EBD850A1A74","latestVersionIndicator":"Yes","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9CD87C9-23A1-08D2-E053-4EBD850A1A74","beginDate":"2022-03-09","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-09","modifiedBy":"ONEDATA","dateModified":"2022-03-09","deletedIndicator":"No"},{"value":"Arm A Haplo HCT","valueDescription":null,"ValueMeaning":{"publicId":"10392382","version":"1","preferredName":"Arm A: Haplo HCT","longName":"10392382v1.00","preferredDefinition":"Arm A: Haplo HCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-A3F5-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-A3F8-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","deletedIndicator":"No"},{"value":"Arm B MUD HCT","valueDescription":null,"ValueMeaning":{"publicId":"10392383","version":"1","preferredName":"Arm B: MUD HCT","longName":"10392383v1.00","preferredDefinition":"Arm B: MUD HCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-A3F6-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-A3F9-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","deletedIndicator":"No"},{"value":"Arm C Haplo HCT","valueDescription":null,"ValueMeaning":{"publicId":"10392384","version":"1","preferredName":"Arm C: Haplo HCT","longName":"10392384v1.00","preferredDefinition":"Arm C: Haplo HCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC439F5-A3F7-2FB6-E053-731AD00AC155","latestVersionIndicator":"Yes","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC439F5-A3FA-2FB6-E053-731AD00AC155","beginDate":"2022-06-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","deletedIndicator":"No"},{"value":"APAL2020B Treatment 10","valueDescription":null,"ValueMeaning":{"publicId":"10542647","version":"1","preferredName":"APAL2020B Treatment 10","longName":"10542647v1.00","preferredDefinition":"APAL2020B Treatment 10","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32BF-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32C5-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"APAL2020B Treatment 20","valueDescription":null,"ValueMeaning":{"publicId":"10542648","version":"1","preferredName":"APAL2020B Treatment 20","longName":"10542648v1.00","preferredDefinition":"APAL2020B Treatment 20","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32C0-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32C6-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"APAL2020B Treatment 30","valueDescription":null,"ValueMeaning":{"publicId":"10542649","version":"1","preferredName":"APAL2020B Treatment 30","longName":"10542649v1.00","preferredDefinition":"APAL2020B Treatment 30","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32C1-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32C7-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"APAL2020B Treatment 40","valueDescription":null,"ValueMeaning":{"publicId":"10542650","version":"1","preferredName":"APAL2020B Treatment 40","longName":"10542650v1.00","preferredDefinition":"APAL2020B Treatment 40","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32C2-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32C8-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"APAL2020B Treatment 90","valueDescription":null,"ValueMeaning":{"publicId":"10542651","version":"1","preferredName":"APAL2020B Treatment 90","longName":"10542651v1.00","preferredDefinition":"APAL2020B Treatment 90","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32C3-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32C9-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"APAL2020B Treatment 100","valueDescription":null,"ValueMeaning":{"publicId":"10542652","version":"1","preferredName":"APAL2020B Treatment 100","longName":"10542652v1.00","preferredDefinition":"APAL2020B Treatment 100","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-32C4-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-32CA-67B5-E053-731AD00AD545","beginDate":"2022-06-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-06-29","modifiedBy":"GDEEN","dateModified":"2022-06-29","deletedIndicator":"No"},{"value":"AOST2032 Dose Level 1","valueDescription":null,"ValueMeaning":{"publicId":"11167520","version":"1","preferredName":"Dose Level 1: Cabozantinib 25mg/m2 (Concomitant Dosing) + MAP","longName":"11167520v1.00","preferredDefinition":"Dose Level 1: Cabozantinib 25mg/m2 (Concomitant Dosing) + MAP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78FAEAC-1443-4E23-E053-731AD00A80A7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeDescription":null,"administrativeNotes":"2022.12.8 Cleaned up alt name and alt def. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-1448-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"AOST2032 Dose Level 2","valueDescription":null,"ValueMeaning":{"publicId":"11167521","version":"1","preferredName":"Dose Level 2: Cabozantinib 35mg/m2 (Concomitant Dosing) + MAP","longName":"11167521v1.00","preferredDefinition":"Dose Level 2: Cabozantinib 35mg/m2 (Concomitant Dosing) + MAP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78FAEAC-1444-4E23-E053-731AD00A80A7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeDescription":null,"administrativeNotes":"2022.12.8 Cleaned up alt name and alt def. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-1449-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"AOST2032 Dose Level 1A","valueDescription":null,"ValueMeaning":{"publicId":"11167522","version":"1","preferredName":"Dose Level 1A: Cabozantinib 25mg/m2 (Sequential Dosing) + MAP","longName":"11167522v1.00","preferredDefinition":"Dose Level 1A: Cabozantinib 25mg/m2 (Sequential Dosing) + MAP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78FAEAC-1445-4E23-E053-731AD00A80A7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeDescription":null,"administrativeNotes":"2022.12.8 Cleaned up Alt VM/def. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-144A-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"AOST2032 Dose Level 2A","valueDescription":null,"ValueMeaning":{"publicId":"11167523","version":"1","preferredName":"Dose Level 2A: Cabozantinib 35mg/m2 (Sequential Dosing) + MAP","longName":"11167523v1.00","preferredDefinition":"Dose Level 2A: Cabozantinib 35mg/m2 (Sequential Dosing) + MAP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78FAEAC-1446-4E23-E053-731AD00A80A7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeDescription":null,"administrativeNotes":"2022.12.8 Cleaned up Alt def/vm. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-144B-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"Regimen C","valueDescription":null,"ValueMeaning":{"publicId":"5170792","version":"1","preferredName":"Regimen C","longName":"5170792","preferredDefinition":"Regimen C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E5546A1-CB3D-D86D-E050-BB89AD4315C3","latestVersionIndicator":"Yes","beginDate":"2016-03-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-18","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.8 Alt def added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-144C-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"Regimen D","valueDescription":null,"ValueMeaning":{"publicId":"11167524","version":"1","preferredName":"Regimen D","longName":"11167524v1.00","preferredDefinition":"Regimen D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78FAEAC-1447-4E23-E053-731AD00A80A7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.8 Alt def added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FAEAC-144D-4E23-E053-731AD00A80A7","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"Regimen A","valueDescription":null,"ValueMeaning":{"publicId":"3395846","version":"1","preferredName":"Regimen A","longName":"3395846","preferredDefinition":"Carboplatin (600 mg/m /dose) and Etoposide (150 mg/m /dose)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA24BDCA-D4B3-7ED9-E040-BB89AD430FDC","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-29","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.8 Alt VM Name added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FC7B1-1BA7-50BA-E053-731AD00A2004","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"Regimen B","valueDescription":null,"ValueMeaning":{"publicId":"3395845","version":"1","preferredName":"Regimen B","longName":"3395845","preferredDefinition":"Ifosfamide  (1800 mg/m /dose) and Etoposide (100 mg/m /dose) and Mesna (1800 mg/m /day) and Filgrastim/G-CSF (5 micrograms/kg/day)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA24BDCA-D490-7ED9-E040-BB89AD430FDC","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2012-02-29","modifiedBy":"KUMMEROA","dateModified":"2022-12-08","changeDescription":null,"administrativeNotes":"2022.12.8 Atl VM name added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E78FC7B1-1BA8-50BA-E053-731AD00A2004","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","deletedIndicator":"No"},{"value":"Aldesleukin","valueDescription":null,"ValueMeaning":{"publicId":"5127432","version":"1","preferredName":"Aldesleukin","longName":"5127432","preferredDefinition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldesleukin","conceptCode":"C1498","definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB5B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA37D84D-7588-7F54-E053-731AD00A3D2B","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","deletedIndicator":"No"},{"value":"ARET2121 Study Treatment","valueDescription":null,"ValueMeaning":{"publicId":"11418059","version":"1","preferredName":"Carboplatin, Vincristine, Etoposide + Intravitreal melphalan injection","longName":"11418059v1.00","preferredDefinition":"Carboplatin, Vincristine, Etoposide + Intravitreal melphalan injection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC8C713-5672-6624-E053-731AD00A03FD","latestVersionIndicator":"Yes","beginDate":"2022-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAC8C713-5673-6624-E053-731AD00A03FD","beginDate":"2022-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-10-11","deletedIndicator":"No"},{"value":"ACCL1931 Arm A","valueDescription":null,"ValueMeaning":{"publicId":"11530606","version":"1","preferredName":"Arm A: Levocarnitine Prophylaxis","longName":"11530606v1.00","preferredDefinition":"Arm A: Levocarnitine Prophylaxis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECA5476B-B7DB-6CA5-E053-731AD00A5DA0","latestVersionIndicator":"Yes","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECA5476B-B7DD-6CA5-E053-731AD00A5DA0","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","deletedIndicator":"No"},{"value":"ACCL1931 Arm B","valueDescription":null,"ValueMeaning":{"publicId":"11530607","version":"1","preferredName":"Arm B: No prophylaxis","longName":"11530607v1.00","preferredDefinition":"Arm B: No prophylaxis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECA5476B-B7DC-6CA5-E053-731AD00A5DA0","latestVersionIndicator":"Yes","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECA5476B-B7DE-6CA5-E053-731AD00A5DA0","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","deletedIndicator":"No"},{"value":"ACCL1931 Arm C","valueDescription":null,"ValueMeaning":{"publicId":"11530608","version":"1","preferredName":"Arm C: Levocarnitine Rescue","longName":"11530608v1.00","preferredDefinition":"Arm C: Levocarnitine Rescue","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECA5F6B2-9581-7EA7-E053-731AD00A1727","latestVersionIndicator":"Yes","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECA5F6B2-9582-7EA7-E053-731AD00A1727","beginDate":"2022-11-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-14","deletedIndicator":"No"},{"value":"Dose Level +1","valueDescription":null,"ValueMeaning":{"publicId":"12020644","version":"1","preferredName":"Dose Level +1","longName":"12020644v1.00","preferredDefinition":"PLX2853 80 mg + Trametinib 2 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED214C5C-193B-1C64-E053-731AD00AF1BE","latestVersionIndicator":"Yes","beginDate":"2022-11-10","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-11-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED214C5C-193C-1C64-E053-731AD00AF1BE","beginDate":"2022-11-10","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-11-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","deletedIndicator":"No"},{"value":"Dose Level -1","valueDescription":null,"ValueMeaning":{"publicId":"3451585","version":"1","preferredName":"Dose Level -1","longName":"3451585","preferredDefinition":"First Dose Level Reduction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF3B7FB7-231E-F21F-E040-BB89AD430439","latestVersionIndicator":"Yes","beginDate":"2012-05-04","endDate":null,"createdBy":"BERGANTW","dateCreated":"2012-05-04","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED22DC42-63A5-4B3B-E053-731AD00AD02C","beginDate":"2022-11-10","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-11-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","deletedIndicator":"No"},{"value":"Dose Level 0","valueDescription":null,"ValueMeaning":{"publicId":"12022550","version":"1","preferredName":"Dose Level 0","longName":"12022550v1.00","preferredDefinition":"Dose Level +1 = PLX2853 80 mg + Trametinib 1.5 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED22E2BB-0C51-4E11-E053-731AD00A41A9","latestVersionIndicator":"Yes","beginDate":"2022-11-10","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-11-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED22E2BB-0C52-4E11-E053-731AD00A41A9","beginDate":"2022-11-10","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-11-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-10","deletedIndicator":"No"},{"value":"SNDX-5613 DL0 + 3-drug re-induction","valueDescription":null,"ValueMeaning":{"publicId":"12987670","version":"1","preferredName":"SNDX-5613 DL0 + 3-drug re-induction","longName":"12987670v1.00","preferredDefinition":"SNDX-5613 DL0 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E4-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51EA-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"SNDX-5613 DL1 + 3-drug re-induction","valueDescription":null,"ValueMeaning":{"publicId":"12987671","version":"1","preferredName":"SNDX-5613 DL1 + 3-drug re-induction","longName":"12987671v1.00","preferredDefinition":"SNDX-5613 DL1 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E5-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51EB-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"SNDX-5613 DL2 + 3-drug re-induction","valueDescription":null,"ValueMeaning":{"publicId":"12987672","version":"1","preferredName":"SNDX-5613 DL2 + 3-drug re-induction","longName":"12987672v1.00","preferredDefinition":"SNDX-5613 DL2 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E6-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51EC-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"SNDX-5613 DL0 + FLA","valueDescription":null,"ValueMeaning":{"publicId":"12987673","version":"1","preferredName":"SNDX-5613 DL0 + FLA","longName":"12987673v1.00","preferredDefinition":"SNDX-5613 DL0 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E7-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51ED-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"SNDX-5613 DL1 + FLA","valueDescription":null,"ValueMeaning":{"publicId":"12987674","version":"1","preferredName":"SNDX-5613 DL1 + FLA","longName":"12987674v1.00","preferredDefinition":"SNDX-5613 DL1 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E8-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51EE-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"SNDX-5613 DL2 + FLA","valueDescription":null,"ValueMeaning":{"publicId":"12987675","version":"1","preferredName":"SNDX-5613 DL2 + FLA","longName":"12987675v1.00","preferredDefinition":"SNDX-5613 DL2 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E9-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F641490B-51EF-7EAB-E053-731AD00A28EE","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","deletedIndicator":"No"},{"value":"Arm B: Bv + Nivo","valueDescription":null,"ValueMeaning":{"publicId":"13233352","version":"1","preferredName":"Arm B: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles","longName":"13233352v1.00","preferredDefinition":"Arm B: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-3247-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-324E-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm C: eBEACOPP + ISRT","valueDescription":null,"ValueMeaning":{"publicId":"13233353","version":"1","preferredName":"Arm C: eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, oncovin, vincristine, prednisone, and procarbazine) x 2 cycles + ISRT","longName":"13233353v1.00","preferredDefinition":"Arm C: eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, oncovin, vincristine, prednisone, and procarbazine) x 2 cycles + ISRT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-3248-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-324F-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm E: AVD","valueDescription":null,"ValueMeaning":{"publicId":"13233355","version":"1","preferredName":"Arm E: AVD x 4 cycles","longName":"13233355v1.00","preferredDefinition":"Arm E: AVD x 4 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-324A-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-3250-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm F: Bv + Nivo","valueDescription":null,"ValueMeaning":{"publicId":"13233356","version":"1","preferredName":"Arm F: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles","longName":"13233356v1.00","preferredDefinition":"Arm F: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-324B-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-3251-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm G: eBEACOPP + ISRT","valueDescription":null,"ValueMeaning":{"publicId":"13233357","version":"1","preferredName":"Arm G: eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, oncovin, vincristine, prednisone, and procarbazine) x 2 cycles + ISRT","longName":"13233357v1.00","preferredDefinition":"Arm G: eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, oncovin, vincristine, prednisone, and procarbazine) x 2 cycles + ISRT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-324C-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-3252-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm H: Bv + Nivo + ISRT","valueDescription":null,"ValueMeaning":{"publicId":"13233358","version":"1","preferredName":"Arm H: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles + ISRT","longName":"13233358v1.00","preferredDefinition":"Arm H: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles + ISRT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-324D-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-3253-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm D: Bv + Nivo + ISRT","valueDescription":null,"ValueMeaning":{"publicId":"13233354","version":"1","preferredName":"Arm D: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles + ISRT","longName":"13233354v1.00","preferredDefinition":"Arm D: Bv + Nivo (Brentuximab vedotin, nivolumab) x 4 cycles + ISRT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7836CB7-3249-399C-E053-731AD00A1049","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7836CB7-3254-399C-E053-731AD00A1049","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"Arm A: ABVD","valueDescription":null,"ValueMeaning":{"publicId":"13233538","version":"1","preferredName":"Arm A: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) x 2 cycles","longName":"13233538v1.00","preferredDefinition":"Arm A: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) x 2 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F783FEC9-E36E-4F77-E053-731AD00ACCBF","latestVersionIndicator":"Yes","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"ZHWENDY","dateModified":"2023-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F783FEC9-E36F-4F77-E053-731AD00ACCBF","beginDate":"2023-03-22","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2023-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"AALL2131 Induction","valueDescription":null,"ValueMeaning":{"publicId":"13267503","version":"1","preferredName":"Induction + Imatinib","longName":"13267503v1.00","preferredDefinition":"Induction + Imatinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8093879-9823-38D9-E053-731AD00ADE41","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":"2023.6.29 Alt VM/Def added per ticket request CADSR0002564. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8093879-9824-38D9-E053-731AD00ADE41","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"All Arms: ABVD","valueDescription":null,"ValueMeaning":{"publicId":"13279328","version":"1","preferredName":"All Arms: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) x 2 cycles","longName":"13279328v1.00","preferredDefinition":"All Arms: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) x 2 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F825EE27-D05D-0E7C-E053-731AD00A3DB0","latestVersionIndicator":"Yes","beginDate":"2023-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-30","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F825EE27-D05E-0E7C-E053-731AD00A3DB0","beginDate":"2023-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-30","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","deletedIndicator":"No"},{"value":"AALL2131 Arm A","valueDescription":null,"ValueMeaning":{"publicId":"13274496","version":"1","preferredName":"Arm A (Chemotherapy + Imatinib)","longName":"13274496v1.00","preferredDefinition":"Arm A (Chemotherapy + Imatinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F812BC7F-22A2-10AD-E053-731AD00A67E9","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":"2023.6.29 Alt VM and Alt def added per ticket request CADSR0002564. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F90ED4E8-B13E-41CE-E053-731AD00ADBC5","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"AALL2131 Arm B","valueDescription":null,"ValueMeaning":{"publicId":"13339380","version":"1","preferredName":"Arm B (Chemotherapy + Imatinib + Blinatumomab)","longName":"13339380v1.00","preferredDefinition":"Arm B (Chemotherapy + Imatinib + Blinatumomab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90ED4E8-B13D-41CE-E053-731AD00ADBC5","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":"2023.6.29 Alt VM and Alt def added per ticket request CADSR0002564. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F90ED4E8-B13F-41CE-E053-731AD00ADBC5","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"AALL2121 Treatment 10","valueDescription":null,"ValueMeaning":{"publicId":"12987670","version":"1","preferredName":"SNDX-5613 DL0 + 3-drug re-induction","longName":"12987670v1.00","preferredDefinition":"SNDX-5613 DL0 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E4-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D01-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"AALL2121 Treatment 20","valueDescription":null,"ValueMeaning":{"publicId":"12987671","version":"1","preferredName":"SNDX-5613 DL1 + 3-drug re-induction","longName":"12987671v1.00","preferredDefinition":"SNDX-5613 DL1 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E5-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D02-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"AALL2121 Treatment 30","valueDescription":null,"ValueMeaning":{"publicId":"12987672","version":"1","preferredName":"SNDX-5613 DL2 + 3-drug re-induction","longName":"12987672v1.00","preferredDefinition":"SNDX-5613 DL2 + 3-drug re-induction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E6-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D03-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"AALL2121 Treatment 40","valueDescription":null,"ValueMeaning":{"publicId":"12987673","version":"1","preferredName":"SNDX-5613 DL0 + FLA","longName":"12987673v1.00","preferredDefinition":"SNDX-5613 DL0 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E7-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D04-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"AALL2121 Treatment 50","valueDescription":null,"ValueMeaning":{"publicId":"12987674","version":"1","preferredName":"SNDX-5613 DL1 + FLA","longName":"12987674v1.00","preferredDefinition":"SNDX-5613 DL1 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E8-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D05-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"AALL2121 Treatment 60","valueDescription":null,"ValueMeaning":{"publicId":"12987675","version":"1","preferredName":"SNDX-5613 DL2 + FLA","longName":"12987675v1.00","preferredDefinition":"SNDX-5613 DL2 + FLA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F641490B-51E9-7EAB-E053-731AD00A28EE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0416899A-1D06-7586-E063-731AD00AD0CE","beginDate":"2023-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"ARAR2221 Treatment","valueDescription":null,"ValueMeaning":{"publicId":"14596617","version":"1","preferredName":"CIT + CRIT + Maintenance IT","longName":"14596617v1.00","preferredDefinition":"CIT + CRIT + Maintenance IT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"094376D9-3851-281E-E063-731AD00A74C7","latestVersionIndicator":"Yes","beginDate":"2023-11-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"094376D9-3852-281E-E063-731AD00A74C7","beginDate":"2023-11-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-11-03","deletedIndicator":"No"},{"value":"Dose painted IMRT","valueDescription":null,"ValueMeaning":{"publicId":"14598283","version":"1","preferredName":"45Gy in 27 fractions with concurrent 54Gy in 27 fractions boost","longName":"14598283v1.00","preferredDefinition":"45Gy in 27 fractions with concurrent 54Gy in 27 fractions boost","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09AA26CE-926B-22D7-E063-731AD00A0E1F","latestVersionIndicator":"Yes","beginDate":"2023-11-08","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-08","modifiedBy":"CLOHNES","dateModified":"2023-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09AA26CE-926D-22D7-E063-731AD00A0E1F","beginDate":"2023-11-08","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-08","modifiedBy":"CLOHNES","dateModified":"2023-11-08","deletedIndicator":"No"},{"value":"3D or sequential IMRT","valueDescription":null,"ValueMeaning":{"publicId":"14598284","version":"1","preferredName":"45Gy in 25 fractions with sequential 9Gy in 5 fraction boost","longName":"14598284v1.00","preferredDefinition":"45Gy in 25 fractions with sequential 9Gy in 5 fraction boost","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09AA26CE-926C-22D7-E063-731AD00A0E1F","latestVersionIndicator":"Yes","beginDate":"2023-11-08","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-08","modifiedBy":"CLOHNES","dateModified":"2023-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09AA26CE-926E-22D7-E063-731AD00A0E1F","beginDate":"2023-11-08","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-11-08","modifiedBy":"CLOHNES","dateModified":"2023-11-08","deletedIndicator":"No"},{"value":"AALL1732 Treatment 140","valueDescription":null,"ValueMeaning":{"publicId":"14706588","version":"1","preferredName":"HR-B-ALL - Arm C Post Consolidation Therapy","longName":"14706588v1.00","preferredDefinition":"HR-B-ALL - Arm C Post Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F4CC091-FB27-203F-E063-731AD00ADCAA","latestVersionIndicator":"Yes","beginDate":"2024-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-19","modifiedBy":"KUMMEROA","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F4CC091-FB29-203F-E063-731AD00ADCAA","beginDate":"2024-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-19","modifiedBy":"KUMMEROA","dateModified":"2024-01-19","deletedIndicator":"No"},{"value":"AALL1732 Treatment 150","valueDescription":null,"ValueMeaning":{"publicId":"14706589","version":"1","preferredName":"MPAL - Post Consolidation Therapy","longName":"14706589v1.00","preferredDefinition":"MPAL - Post Consolidation Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F4CC091-FB28-203F-E063-731AD00ADCAA","latestVersionIndicator":"Yes","beginDate":"2024-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-19","modifiedBy":"KUMMEROA","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F4CC091-FB2A-203F-E063-731AD00ADCAA","beginDate":"2024-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-19","modifiedBy":"KUMMEROA","dateModified":"2024-01-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B658474C-8270-BD53-E040-BB89AD433481","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-12","modifiedBy":"KUMMEROA","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"2024.1.19 PVs added per ticket request CADSR0003301. ak 2023.11.3 PV added per ticket request CADSR0003032. ak 2023.8.29 PVs added per ticket request CADSR0002790 but notified customer that these PVs will be duplicates to what already exists but was told to add.  ak 2023.4.11 PVs added per ticket request CADSR0002292. ak 2023.3.30 Per Lynn at COG updated PVs for Arms a-h. ak 2023.3.22: PVs added per ticket CADSR0002119.wz 2023.3.6 PVs added per ticket request CADSR0002119. ak 2022.8.31 Added PVs per ticket request CADSR0001472. ak 2022.10.11 PV added for ticket request CADSR0001571. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"TxAssTp","type":"COG GDE Short Name","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"TXASSTP_ELI","type":"COG Form Element","context":"COG"},{"name":"TXASSTP_CALLB","type":"COG Form Element","context":"COG"},{"name":"TXASSTP_CALLBACK","type":"COG Form Element","context":"COG"},{"name":"PR_PRTRT_IMRT","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Study Treatment","type":"Preferred Question Text","description":"Study Treatment","url":null,"context":"COG"},{"name":"CRF Text1","type":"Alternate Question Text","description":"AALL08B1 Treatment","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"AALL0921 Treatment","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"ABTR01B1 Treatment","url":null,"context":"CTEP"},{"name":"COG Text 1","type":"Alternate Question Text","description":"Treatment:","url":null,"context":"CTEP"},{"name":"COG Text 2","type":"Alternate Question Text","description":"ANBL1221 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"ASCT1221 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"ACNS1221 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"ACCL1034 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"ANHL12P1 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"ADVL1321 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"ARET12P1 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"ARST1321 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"AEWS1221 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"AOST1322 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"ANBL1232 Treatment based on biology results:","url":null,"context":"CTEP"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"AALL1331 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"AALL1231 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"AALL1331 Treatment Assignment:","url":null,"context":"COG"},{"name":"COG CRF Text 21","type":"Alternate Question Text","description":"APEC14B1 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 17","type":"Alternate Question Text","description":"AAML1331 Treatment:","url":null,"context":"CTEP"},{"name":"COG CRF Text 16","type":"Alternate Question Text","description":"AHOD1331 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 18","type":"Alternate Question Text","description":"AAML1531 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 19","type":"Alternate Question Text","description":"ADVL1522 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 20","type":"Alternate Question Text","description":"AOST1321 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 22","type":"Alternate Question Text","description":"AOST1421 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 23","type":"Alternate Question Text","description":"AAML1421 Treatment","url":null,"context":"CTEP"},{"name":"COG CRF Text 24","type":"Alternate Question Text","description":"AOST1521 Treatment:","url":null,"context":"CTEP"},{"name":"COG CRF Text 25","type":"Alternate Question Text","description":"ALTE1621 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 28","type":"Alternate Question Text","description":"ALTE11C1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 26","type":"Alternate Question Text","description":"ARST1431 Treatment:","url":null,"context":"CTEP"},{"name":"COG CRF Text 27","type":"Alternate Question Text","description":"ALTE11C2 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 29","type":"Alternate Question Text","description":"ACNS1422 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 32","type":"Alternate Question Text","description":"APEC14B1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 31","type":"Alternate Question Text","description":"ALTE15N2 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 30","type":"Alternate Question Text","description":"ACCL0631 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 38","type":"Alternate Question Text","description":"AALL1631 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 34","type":"Alternate Question Text","description":"ANHL1522 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 33","type":"Alternate Question Text","description":"AALL15P1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 35","type":"Alternate Question Text","description":"ADVL1622 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 37","type":"Alternate Question Text","description":"AGCT1531 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 36","type":"Alternate Question Text","description":"AALL1621 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 43","type":"Alternate Question Text","description":"ANBL1531 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 42","type":"Alternate Question Text","description":"ACCL1633 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 40","type":"Alternate Question Text","description":"ALTE16C1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 41","type":"Alternate Question Text","description":"ALTE1631 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 44","type":"Alternate Question Text","description":"ADVL1521 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 39","type":"Alternate Question Text","description":"ANBL1531 Treatment:","url":null,"context":"COG"},{"name":"NRG_CRF Text 1","type":"Alternate Question Text","description":"Which treatment option will the patient continue on","url":null,"context":"NRG"},{"name":"COG CRF Text 45","type":"Alternate Question Text","description":"AGCT1532 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 46","type":"Alternate Question Text","description":"AHEP1531 Treatment:","url":null,"context":"COG"},{"name":"cog crf test 47","type":"Alternate Question Text","description":"Treatment Assignment","url":null,"context":"COG"},{"name":"COG CRF Text 100","type":"Alternate Question Text","description":"Study Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 48","type":"Alternate Question Text","description":"ADVL1823 Treatment:","url":null,"context":"COG"},{"name":"COG CRF TEXT 47","type":"Alternate Question Text","description":"ANBL17P1 Treatment","url":null,"context":"COG"},{"name":"COG CRF TEXT48","type":"Alternate Question Text","description":"AAML18P1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 50","type":"Alternate Question Text","description":"ACNS1831 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 49","type":"Alternate Question Text","description":"ANBL1821 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 61","type":"Alternate Question Text","description":"AALL1731 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 103","type":"Alternate Question Text","description":"AALL1731 Post-Consolidation Therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 102","type":"Alternate Question Text","description":"AALL1731 Post Consolidation Therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 51","type":"Alternate Question Text","description":"ACNS1833 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 101","type":"Alternate Question Text","description":"AALL1731 New Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 60","type":"Alternate Question Text","description":"AALL1731 New Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 300","type":"Alternate Question Text","description":"AALL1732 New Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 65","type":"Alternate Question Text","description":"AALL1732 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 200","type":"Alternate Question Text","description":"AALL1732 treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 52","type":"Alternate Question Text","description":"AAML1831 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 66","type":"Alternate Question Text","description":"AAML1831 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 62","type":"Alternate Question Text","description":"ADVL18P1 treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 67","type":"Alternate Question Text","description":"AAML1831 Treatment Arm:","url":null,"context":"COG"},{"name":"COG CRF Text 63","type":"Alternate Question Text","description":"ALTE2031 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 68","type":"Alternate Question Text","description":"ARST1921 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 69","type":"Alternate Question Text","description":"ACNS1931 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 53","type":"Alternate Question Text","description":"AREN1921 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 104","type":"Alternate Question Text","description":"ACCL2031 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 70","type":"Alternate Question Text","description":"ANBL19P1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF 760","type":"Alternate Question Text","description":"AALL1821 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 256","type":"Alternate Question Text","description":"AALL1821 Treatment Assignment:","url":null,"context":"COG"},{"name":"COG CRF Text  761","type":"Alternate Question Text","description":"ANHL1931 Treatment:","url":null,"context":"COG"},{"name":"ARST2031 Treatment","type":"Alternate Question Text","description":"ARST2031 Treatment:","url":null,"context":"COG"},{"name":"COG CRF TEXT 71","type":"Alternate Question Text","description":"APAL2020SC Treatment:","url":null,"context":"COG"},{"name":"AOST2031 Treatment","type":"Alternate Question Text","description":"AOST2031 Treatment","url":null,"context":"COG"},{"name":"COG CRF Text 105","type":"Alternate Question Text","description":"ASCT2031 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 106","type":"Alternate Question Text","description":"ANHL2121 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 107","type":"Alternate Question Text","description":"ASCT2121 Treatment:","url":null,"context":"COG"},{"name":"ARST2032 Treatment","type":"Alternate Question Text","description":"ARST2032 Treatment","url":null,"context":"COG"},{"name":"COG CRF text 72","type":"Alternate Question Text","description":"ACCL21C2 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 73","type":"Alternate Question Text","description":"APAL2020B Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 54","type":"Alternate Question Text","description":"Actual treatment patient received:","url":null,"context":"COG"},{"name":"COG CRF Text 55","type":"Alternate Question Text","description":"AOST2032 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 56","type":"Alternate Question Text","description":"ARET2121 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 57","type":"Alternate Question Text","description":"ACCL1931 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 58","type":"Alternate Question Text","description":"ACCL1931 New Treatment:","url":null,"context":"COG"},{"name":"Alliance Text 1","type":"Alternate Question Text","description":"Dose Level assignment","url":null,"context":"Alliance"},{"name":"COG CRF Text 59","type":"Alternate Question Text","description":"AALL2131 Treatment:","url":null,"context":"COG"},{"name":"ALTE21C1 Treatment:","type":"Alternate Question Text","description":"ALTE21C1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 74","type":"Alternate Question Text","description":"ALTE22C1 Treatment:","url":null,"context":"COG"},{"name":"COG CRF text 75","type":"Alternate Question Text","description":"AALL2121 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 64","type":"Alternate Question Text","description":"AHOD2131 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"ACCL1932 Treatment:","url":null,"context":"COG"},{"name":"COG CRF Text 76","type":"Alternate Question Text","description":"ARAR2221 Treatment:","url":null,"context":"COG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Which treatment option was chosen?","url":null,"context":"CCTG"},{"name":"COG CRF Text 78","type":"Alternate Question Text","description":"ANBL2131 Treatment:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B412D276-C256-DB73-E040-BB89AD433B53","latestVersionIndicator":"Yes","beginDate":"2011-12-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-12-14","modifiedBy":"KUMMEROA","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":"202401.4 AQT added per ticket request CADSR-TASK0003337. ak 11/7/23 Added AQT and alt OID, CCTG for CCTG for ticket number CADSR0003018 cjl; 2023.11.3 AQT added per ticket request CADSR0003032. ak 2023.4.4 AQT added per ticket request CADSR0002268. ak 2023.3.21 AQT/Alt SN added per ticket request CADSR0002164. ak 2023.3.3 AQT added per ticket request CADSR0002119. ak 2023.1.17 AQT added per ticket request CADSR-TASK0001943. ak 2022.8.31 Added AQT per ticket request CADSR0001472. ak 2022.10.11 AQT added for ticket request CADSR0001590. ak 2022.11.4 AQT added for ticket request CADSR0001656. ak","unresolvedIssues":null,"deletedIndicator":"No"}}